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ABSTRACT 
 
β-lactone containing natural products are attractive targets for total synthesis and 
subsequent biological studies.  Given the remarkable ability of this moiety to covalently 
inhibit specific proteins, we were drawn to spongiolactone as a synthetic target.  
Through our studies, the first total synthesis of this compound was achieved 
along with the synthesis of several derivatives.  This synthesis enabled cytotoxicity 
studies to be carried out against a variety of cancer cell lines, with good activity 
observed in the human chronic myelogenous leukemia (K562) cell line.  Particularly 
intriguing was the discovery of a more potent derivative than the natural product itself 
which was then modified and taken on to activity based protein profiling (ABPP) 
studies. 
The first magnetite-supported benzotetramisole (BTM) catalyst was prepared and 
utilized in the kinetic resolution of secondary alcohols.  Overall, the selectivity factor 
was lower than the parent (+)-BTM (s = 48 versus s = 148, respectively), however the 
resulting ester was achieved in excellent enantiomeric excess, albeit with low reaction 
conversion.  Further studies suggest an unfavorable inactivation of the catalyst taking 
place in the presence of uncapped magnetite. 
The first soluble, polymer-supported BTM catalyst was also synthesized using 
polyisobutylene as the support.  Behavior of this catalyst system was superior to the 
magnetite-BTM adduct in the kinetic resolution of secondary alcohols and the 
conversion was efficient, providing the resolved alcohol and ester both in 90% ee which 
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corresponds to a selectivity factor of 79.  Preliminary studies show problems of 
recyclability as indicated by the drop in selectivity factor (s = 51) and increase in 
reaction time to 16 hours.  Further studies are necessary toward recoverability and 
recyclability of this system. 
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CHAPTER I  
INTRODUCTION TO SPONGIANE DITERPENOID NATURAL PRODUCTS 
 
1.1 Introduction 
The enzyme-catalyzed cyclization of geranylgeranyl diphosphate leads to diverse 
structural skeletons broadly described as diterpenoids.
1
  The biological value of these 20-
carbon units has been proven with natural products such as taxol, driving forward the 
investigation into other diterpenoids.  Following the isolation of several diterpenoids 
from marine sponges, all of which shared a common skeleton (1.1), the term spongiane 
diterpenoid was adopted in 1979 (Figure 1.1).   
 
 
Figure 1.1 Common skeleton to spongiane diterpenoids. 
 
1.2 Isolation of Spongiane Diterpenoids 
The first spongiane diterpenoid, isoagatholactone (1.2), was isolated in 1974 by 
Minale and coworkers from the Mediterranean sponge Spongia officinalis.
2
 (Figure 1.2).   
 2 
 
 
Figure 1.2 Examples of isolated spongiane diterpenoids. 
 
Since this time, many other natural products have been added to this class of 
compounds, with varying levels of oxidation on the spongiane skeleton.  Examples 
include aplysillin (1.3), isolated off the coast of New Zealand from marine sponge 
Aplysilla rosea
3
 as well as spongia-15, 16-dione (1.4)
4
 from the sponge Dictyodendrilla 
cavernosa.  
In 1985, the spongiane diterpenoid class of natural products was expanded 
beyond the originally defined tetracyclic core.  During their studies of the metabolites of 
Spongionella gracilis isolated off the coast of Italy, Sica and coworkers discovered the 
first rearranged spongiane diterpenoid, norditerpene gracilin A (1.5) (Figure 1.3).
5
   
 
 
Figure 1.3 The first isolated rearranged spongiane diterpenoid. 
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Today, these rearranged natural products comprise the largest portion of known 
spongiane diterpenoids.  Other closely related spongiane diterpenoids have been 
isolated, such as aplysillolide A (1.7) and B (1.8) from the sponge Aplysilla glacialis 
which contain the same core structure as gracilin A (1.5)
6
 (Figure 1.4).  The separately 
isolated natural product dendrillin (1.9) also contains a gracilin-type skeleton, albeit 
from Antarctic sponge Dendrilla membranosa.
7
 
 
 
Figure 1.4 Other examples of rearranged spongiane diterpenoids. 
 
Tricyclic diterpene lactones, such as cadlinolide A (1.10)
6
 and 
tetrahydroaplysulfurin
6
 (1.11)  have demonstrated further structural diversity in the 
rearranged spongiane diterpenoids.  Other isolates, such as pourewanone (1.12),
8
 the first 
reported marine formate, and metabolites such as that from Dendrilla membranosa 
(1.13)
9
 which contain a carboxylic acid or lactone, respectively. 
 4 
 
The presence of these groups provides insight into a possible biosynthetic 
pathway (Scheme 1.1).  
 
Scheme 1.1 
 
 
 
Here, it is thought that, following initial oxidation of the spongiane diterpenoid 
skeleton (1.14), a Wagner-Meerwein rearrangement takes place.
10
  Further oxidation 
provides 1.17, which, if followed by decarboxylation or cyclization, leads to the 
gracilins as well as tricyclic rearranged spongiane diterpenoids. 
 
1.3 Selected Synthetic Studies of Spongiane Diterpenoids 
The first reported synthesis of a spongiane diterpenoid was in 1981 by Rứveda 
and coworkers, detailing the synthesis of (+)-isoagatholactone (1.2) (Scheme 1.2).
11
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Scheme 1.2 
 
 
 
Beginning with oxidation of chiral starting material (+)-manool (1.19) followed 
by acid-catalyzed cyclization, known intermediate ent-methyl isocopalate (1.21) was 
formed.  Subsequently, allylic alcohol (1.22) was accessed via photooxygenation which 
was followed by an allylic rearrangement/lactonization, providing 1.23.  Reduction of 
the lactone and oxidation/lactonization provided (+)-isoagatholactone (1.2) for the first 
time. 
The first reported total synthesis of a rearranged spongiane diterpenoid was by 
Overman and coworkers in 2001 where they were able to not only access (+)-shahamin 
K (1.25) in a laboratory setting for the first time, but also confirm its relative and 
absolute stereochemistry.
12
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Retrosynthetically, it was envisioned that (+)-shahamin K could ultimately be 
derived from a Michael addition between the enolate of hydroazulene 1.27 and the 
corresponding cyclopentenone (1.26) (Scheme 1.3).  Hydroazulene 1.27 would be 
constructed via a key ring expansion/annulation of the elaborated cyclohexane precursor 
1.28. 
 
Scheme 1.3 
 
 
 
 Beginning with cyclohexanone 1.29, Lemieux–Johnson oxidation of the olefin 
followed by dithioacetal formation afforded 1.30 which was then subjected to kinetic 
resolution to achieve highly enantioenriched 1.33 (Scheme 1.4).  Subsequent 
transformations led to silyl ether 1.28 that underwent a Prins-pinacol rearrangement 
mediated by dimethyl(methylthio)sulfonium tetrafluoroborate (DMTSF) to give cis 
hydroazulene 1.34.  Upon enolate formation of cyclopentanone 1.35, Michael addition to 
1.26 successfully formed the key C8-C14 bond.  Additional manipulations allowed them 
to arrive at advanced intermediate 1.36 which upon oxidation mediated by lead 
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tetraacetate, reduction of the resulting aldehyde, and lactonization afforded (+) shahamin 
K (1.25). 
 
Scheme 1.4 
 
 
 
Adding to the reported chemistries of the spongiane diterpenoid family, the 
enantioselective synthesis of (+)-norrisolide (1.39) was reported in 2004 by Theodorakis 
and coworkers.
13
  From the structural standpoint, norrisolide presented an interesting 
 8 
 
challenge as it contains a γ-lactone, γ-lactol ring system.  Norrisolide was the first 
spongiane diterpenoid with this highly oxygenated moiety to succumb to total synthesis. 
Retrosynthetically, it was thought that late stage oxygenation of a highly 
advanced intermediate (1.40) would provide access to norrisolide (Scheme 1.5).  This 
late stage intermediate could arise from a direct coupling between vinyl iodide 1.42 and 
aldehyde 1.41, where 1.42 could be derived from enone (+)-1.43 and aldehyde 1.41 
could come from lactone 1.44.  
 
Scheme 1.5 
 
 
 The forward route began with optically active enone (+)-1.39 which was 
converted to silyl ether 1.45 over a few steps (Scheme 1.6).  This was followed by 
Barton-McCombie radical deoxygenation to access bicyclic cyclopentene 1.46 in 
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excellent yield.  Subsequent desilylation and oxidation afforded cyclopentanone 1.47 
which was taken on in a few steps to the desired vinyl iodide 1.42.   
 
Scheme 1.6 
 
 
 
 Accessing aldehyde coupling partner 1.41 began with a Diels-Alder reaction to 
afford bicyclic cyclohexene 1.44 as a single isomer with the facial preference controlled 
by the bulky silyl group (Scheme 1.7).  DIBAL-H reduction followed by 
dihydroxylation and oxidation yielded requisite aldehyde 1.45 which was taken on in a 
few steps to achieve necessary coupling partner 1.41.   
 
 
 
 
 
 10 
 
Scheme 1.7 
 
 
 
 With the two pieces in hand, lithium halogen exchange of 1.42 afforded the 
appropriate nucleophile for aldehyde 1.41 and the resulting aldol adduct was oxidized to 
give ketone 1.50 that was further elaborated to 1.40 and, ultimately, norrisolide 1.39 
(Scheme 1.8).   
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Scheme 1.8 
 
 
 
The first total synthesis of members of the gracilin family of rearranged 
spongiane diterpenoids was reported in 1995 by Corey and coworkers.
14
  Given their  
previously published catalytic, highly enantioselective Diels-Alder reaction,
15
 they not 
only sought to access this family of natural products for the first time but also saw these 
targets as a powerful synthetic application for their methodology. 
 Retrosynthetically, it was envisioned that both gracilin B (1.51) and gracilin C 
(1.52) could both be accessed from late-stage alcohol 1.53 (Scheme 1.9).  This common 
intermediate could be formed via an aldol reaction between aldehyde 1.54 and tricyclic 
lactone 1.55. Lactone 1.55 could arise through acetal formation of an aldehyde acid 
precursor 1.56 that could be formed through oxidative cleavage of bicyclic cyclohexene 
acetal 1.57 that would ultimately be achieved from an enantioselective Diels-Alder 
reaction between diene 1.58 and dienophile 1.59. 
 12 
 
Scheme 1.9 
 
 
  
 The synthesis commenced with the previously developed enantioselective Diels-
Alder reaction to provide cyclohexene 1.61 in excellent yield and enantiomeric excess 
(Scheme 1.10).  Subsequent steps provided dialdehyde 1.62 which was advanced to 
cyclic bis acetal 1.63.  Oxidative cleavage mediated by osmium tetroxide provided 
aldehyde acid 1.56 which formed tricyclic lactol 1.64 under acidic conditions.  This 
lactol was converted to tricyclic vinyl ether lactone 1.55 and a final aldol reaction with 
aldehyde 1.54 gave common intermediate 1.53.    
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Scheme 1.10 
 
 
 
 Access to both gracilin B and C was achieved by intermediate 1.53 (Scheme 
1.11).  For gracilin C, acetylation of the secondary alcohol followed by elimination 
afforded triene 1.65’ in excellent yield which was easily transformed into gracilin C 
(1.52) through epoxidation, acetolysis, and acetylation.  Accessing gracilin B utilized 
stereospecific dehydration to provide the necessary triene (1.65) which was taken 
through the same sequence to achieve gracilin B (1.51). 
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Scheme 1.11 
 
 
 
1.4 Biological Studies of the Spongiane Diterpenoids 
 The spongiane diterpenoids display a broad spectrum of biological activity 
including, but not limited to anticancer, inhibition against tyrosine kinase, phospholipase 
A2 (PLA2)/anti-inflammatory, and neoroprotective properties.  Extensive investigation 
into gracilins B (1.51) and C (1.52) (Figure 1.5) showed micromolar GI50 values 
(concentration of compound of interest required to cause 50% growth inhibition) in 
twelve different cancer cell lines including pancreatic, cervical, prostate, lung, breast, 
ovarian, colon, leukemia, and melanoma.
16,17
  
 
 15 
 
 
Figure 1.5 Spongiane diterpenoids that display anticancer activity. 
 
Toward specific treatment of prostate cancer, spongia-13(16), 14-dien-19-oic 
acid 1.66 was found to block androgen receptor transcription and specifically inhibit 
cell-proliferation that relies on androgen.
18
 
Gracilin A (1.5) has demonstrated up to 69% inactivation of phospholipase A2, 
which has implications toward anti-inflammatory activity.  A separate investigation 
(Figure 1.6) of cadlinolide C (1.67), methylpourewate B (1.68),and pourewic acid A 
(1.69) also showed moderate levels of anti-inflammatory activity.
8
 
 
 
Figure 1.6 Spongiane diterpenoids displaying anti-inflammatory activity. 
 
 More recent literature reported spongiane diterpenoids, specifically 
tetrahydroaplysulphurin-1 (1.11) along with gracilins A (1.5), H (1.70), K (1.72), J 
(1.71), and L (1.73) (Figure 1.7) to have neuroprotective properties.
19
   
 16 
 
 
Figure 1.7 Members of the gracilin family that display neuroprotective properties. 
 
In these studies, the compounds mentioned were used in the presence of 
hydrogen peroxide, which is known to induce oxidative stress, and the level of oxidative 
damage on the cells was measured.  Tetrahydroaplysulphurin-1 (1.11) showed 
exceptional results, completely protecting against neurodamage.   
 Gracilins A (1.5), H (1.69), and L (1.72) along with tetrahydroaplysulphurin-1 
2.x were also evaluated for their ability to reduce hyperphosphorylation of tau proteins, 
which is linked to the progression of Alzheimer’s disease.20  Gracilins H (1.70) and L 
(1.73) were even evaluated in vivo in chronic Alzheimer’s disease mice which showed, 
after treatment, improved spatial memory and learning.  
 
 
 
 
 
 
 17 
 
CHAPTER II  
TOTAL SYNTHESIS OF (+)-SPONGIOLACTONE AND RELATED 
COMPOUNDS
*
 
 
2.1 Introduction 
Presenting a highly rearranged spongiane skeleton and a unique fused -lactone, 
(+)-spongiolactone (2.1) was first isolated in 1986 by Sica and coworkers from the 
sponge Spongionella gracilis (Figure 2.1).
21
   
 
 
Figure 2.1 β-lactone containing spongiane diterpenoids. 
 
In 2009, a related congener was isolated by Jaspers, C3’-norspongiolactone (2.2), 
differing only by a methyl group in the side-chain ester, and found to possess 
antiproliferative activity toward human chronic mylogenous leukemia cells (K562, IC50 
12 ± 1 M) and potential immunosuppressive activity through inhibition of human 
peripheral blood mononuclear cells (PBMC, IC50 30 ± 10 M).
17 
Despite the presence of 
                                                 
*
 Reprinted with permission from  “Synthesis of (±)-Spongiolactone Enabling Discovery of a More Potent 
Derivative“ by Harvey, N. L.; Krysiak, J.; Chamni, S.; Cho, S. W.; Sieber, S. A.; Romo, D. Chem. Eur, J. 
2015, 21, 1425-1428. Copyright 2015 John Wiley and Sons, Weinheim.  See Appendix C. 
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the resident -lactone, with potential as a protein-reactive, acylating pharmacophore, 
neither synthetic nor mechanism of action studies have been reported for the 
spongiolactones. 
 
2.1.1 Previous Studies Toward Spongiolactone 
 The initial retrosynthetic analysis envisioned accessing (+)-spongiolactone by a 
late stage esterification and dehydration of elaborated tricyclic β-lactone 2.1 (Scheme 
2.1).  The all-carbon quaternary center directly adjacent to the tertiary alcohol of 2.3 
would be installed by addition of separately prepared allyl zinc reagent 2.4 to tricyclic β-
lactone 2.8 which could arise via a nucleophile-catalyzed aldol lactonization of an 
intermediate aldehyde-acid derived from trisubstituted cyclohexanone 2.6.  The 
cyclohexanone could come from a cuprate addition to enone 2.7 that could easily be 
derived utilizing a Stork-Danheiser enone synthesis of β-keto enol ether 2.8 which could 
be formed from commercially available 1,3-cyclohexanedione 2.9.    
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Scheme 2.1 
 
 
 
2.1.2 Synthesis of β-lactones via the Intramolecular, Nucleophile Catalyzed Aldol-
Lactonization (NCAL) Process  
 
 In the Romo group, extensive work has been contributed to the literature 
detailing the synthesis of β-lactones.  Specifically, this work has focused on a 
nucleophile catalyzed aldol-lactonization process developed in the group.  Since its 
seminal report
22
, this process has evolved with respect to the substrate scope amenable to 
the transformation from aldehyde acids
23-26
 to keto acids
27, 28
 (Scheme 2.2). 
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Scheme 2.2 
 
 
 
This methodology has been carried out in a double diastereoselective fashion 
with optically active aldehyde acids
25
 with an extension to β-lactone fused 
tetrahydrofurans, and further work displayed the use of keto acids to generate bi- and tri-
cyclic β-lactones in an enantioselective, organocatalytic NCAL process.28 
  Most recently, a nucleophile catalyzed, Michael aldol-β-lactonization (NCMAL) 
organocascade
29
 (Scheme 2.3) was described to rapidly generate complex cyclopentanes 
(2.15).   
 
Scheme 2.3 
 
 
 
Utilizing commodity acid chlorides (2.13), a highly reactive, chiral α, β-
unsaturated acylammonium intermediate is generated which then participates in the 
 21 
 
organocascade process to generate up to three contiguous stereogenic centers, two rings, 
one C-O bond, and two C-C bonds in high enantiomeric excess. 
The β-lactones synthesized by these methodologies have been used to access β-
lactone containing natural products, such as (-)-salinosporamide A 2.15, as well as to set 
key stereogenic centers in a molecule
30-32
 through further manipulations: a strategy used 
toward (+)-dihydroplakevulin A (2.16),
27
 (-)-curcumanolide A (2.17),
32
 and (+)-
omphadiol (2.18) (Figure 2.2).
31
   
 
 
Figure 2.2 Natural products synthesized with the NCAL as a key step. 
 
The total synthesis of (+)-dihydroplakevulin 2.16 was the fruit of the extension of 
the NCAL process to keto acid substrates (Scheme 2.4).
27
  Before these reported studies, 
the yields for these substrates were <5%.   
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Scheme 2.4  
 
 
 
Ultimately, switching to pyridine derivatives, such as 4-pyrrolidinopyridine, 
which have a higher nucleophilicity than the previously examined triethylamine, enabled 
the bis-cyclization process to proceed and opened the door to asymmetric 
transformations.  With the required stereogenic centers of the molecule set by the β-
lactonization process, (+)-dihydroplakevulin was accessed by a few further functional 
group interconversions. 
To access (-)-curcumanolide A (2.17), the NCAL reaction was applied to keto 
acid 2.22 to form tricyclic β-lactone 2.23 (Scheme 2.5).  This β-lactone then underwent a 
dyotropic rearrangement to provide spiro-γ-butyrolactone 2.24 which was then taken on 
to the natural product. 
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Scheme 2.5 
 
 
 
 A third example of using an intermediate β-lactone to set key stereogenic centers 
in a total synthesis is (+)-omphadiol 2.18 (Scheme 2.6).  In this case, a keto acid derived 
from (R)-carvone 2.25 was subjected to the NCAL process, leading to β-lactone 2.26 in  
highly diastereoselective fashion.  This key intermediate was further manipulated to 
access (+)-omphadiol 2.18 for the first time. 
 
Scheme 2.6 
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2.1.3 Proposed Mechanism for the Intramolecular, Nucleophile Catalyzed Aldol-
Lactonization (NCAL) Process  
Mechanistically, the nucleophile catalyzed aldol-lactonization process begins by 
activation of the carboxylic acid of the parent aldehyde acid or keto acid 2.28 (Scheme 
2.7).  Activated intermediate 2.29 can then undergo two separate pathways.  Following 
Pathway 1, nucleophilic addition by a tertiary amine, such as O-TMS quinine or O-TMS 
quinidine, or an isothiourea catalyst, such as benzotetramisole (BTM) or 
homobenzotetramisole (HBTM), leads to acylammonium 2.30.  Deprotonation of 
acylammonium 2.30 leads to ammonium enolate intermediate 2.31 that can then undergo 
an aldol reaction with the pendant carbonyl leading to 2.32.  This aldol adduct can then 
undergo β-lactonization and turnover the catalyst.   
Alternatively, activated intermediate 2.29 can form ketene 2.35 via Pathway 2.  It 
should be noted that the same ketene can result from acylammonium 2.30.  This ketene 
can then undergo a [2 + 2] cycloaddition with the pendant carbonyl yielding the same β-
lactone 2.34 as Pathway 1. 
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Scheme 2.7 
 
 
 
 From the studies carried out in the Romo group, Pathway 1 is favored given the 
ability to generate β-lactones in high enantiomeric excess, indicating the chiral 
nucleophilic promoter is present during the aldol process. 
 
2.1.4 Allylzinc Reagents as a Means to Install All-Carbon Quaternary Centers 
 The controlled formation of all-carbon quaternary centers continues to challenge 
synthetic chemists.  Several methods are available to complete this task,
33-35
 including 
but not limited to alkylations, conjugate additions, rearrangements, Diels-Alder 
reactions, and allylic substitutions.  In considering the system specific to spongiolactone, 
we were drawn to allyl zinc reagents as a means to forge a necessary all-carbon 
quaternary center adjacent to a tertiary alcohol.   
Allyl zinc reagents are known to undergo SE’ addition to carbonyls in a highly 
regioselective manner, predicated on a proposed highly ordered chair-like, closed 
 26 
 
transition state arrangement 2.42 (Scheme 2.8),
36
 are tolerant to other functional groups, 
and are relatively stable.  This is in contrast to allylic magnesium and lithium species 
which are highly reactive and often unstable. 
 
Scheme 2.8 
 
 
 
The preparation of allyl zinc reagents was not always a straightforward process.  
In early studies toward allyl zinc reagents, the use of highly reactive zinc, such as Rieke 
zinc,
37
 made their use less appealing.  In 2006, Knochel and coworkers reported milder 
conditions
38
 utilizing lithium chloride to facilitate the formation of alkyl and aryl-zinc 
compounds with commercially available zinc dust (Scheme 2.9).   
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Scheme 2.9 
 
 
 
This work was centered around the use of either iodine or bromine as the 
halogenated precursor (2.44), since these species are more reactive toward formation of 
the zinc reagent.  Specifically considering substituted alkyl systems, this high reactivity 
was detrimental and, in fact, large amounts of homocoupling was observed.
36
  In a 
follow-up report in 2007, Knochel and coworkers detailed the use of less reactive 
substituted allyl chlorides (2.47) in the presence of lithium chloride, under mild reaction 
conditions, to overcome this problem (Scheme 2.10). 
 
Scheme 2.10 
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The prepared allyl zinc reagents were added to a variety of carbonyl electrophiles 
to produce all-carbon quaternary centers adjacent to tertiary alcohols in excellent yield 
and diastereoselectivity (Scheme 2.11). 
 
Scheme 2.11 
 
 
 
 Applying these reagents to more complex systems, studies were reported on α-
chiral carbonyl compounds (Scheme 2.12).  In this case, a variety of α-substituents 
(2.62-2.65) were examined, all providing excellent diastereoselectivity and yield, 
analogous to previous studies on simpler systems. 
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Scheme 2.12 
 
 
 
While these results show the utility of allyl zinc reagents to install all-carbon 
quaternary centers, the most substituted systems for which this reaction is applied 
contained only an α-substituent. 
 
2.2 Results and Discussion 
2.2.1 Synthesis of Tricyclic β-lactone Core Toward Spongiolactone and Attempted 
SE’ Addition   
The synthesis commenced with a scaleable two-stage, one-pot sequence 
involving conversion of 1,3-cyclohexanedione (2.9) to β-keto enol ether 2.8 through an 
initial Michael addition with t-butyl acrylate followed by O-alkylation in 90% overall 
yield (Scheme 2.13).  Application of a kinetic alkylation with benzyl chloromethyl ether 
exclusively afforded α-benzyloxymethylene adduct (±)-2.70 through careful control of 
reaction temperature to ensure kinetic deprotonation.  A Stork-Danheiser cyclohexenone 
synthesis
39
 involving Luche reduction
40
 and acidic workup directly provided 
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cyclohexenone (±)-2.7.  Addition of isobutenyl cuprate to this enone in the presence of 
Me3SiCl provided a single diastereomer (>19:1 by 500 MHz
 1
H NMR) of  an 
intermediate silylenol ether
41
 which was typically directly desilylated through an acidic 
workup to yield the anti,anti-trisubstituted cyclohexanone (±)-2.6 as an inseparable 7:1 
mixture of diastereomers, epimeric at the C8-stereocenter. 
 
Scheme 2.13 
 
 
 
Treatment with trifluoroacetic acid (TFA) easily converted the t-butyl ester to the 
carboxylic acid.  Ozonolysis of the trisubstituted olefin afforded aldehyde acid (±)-2.71 
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which was then applied to the NCAL process to give products 2.5 and 2.5’ which are 
diastereomeric at the β-lactone.  
With β-lactone 2.5 in hand, the next step was the chemoselective SE’ addition of 
allyl zinc reagent 2.4 to ketone 2.5.  To our disappointment, the desired transformation 
did not occur (Scheme 2.14) and the starting material was recovered even if the reaction 
was warmed to 0 ˚C.  It should be noted that another general problem with this reaction 
was the inconsistent preparation of allyl zinc reagent 2.4. 
 
Scheme 2.14 
 
 
 
Interestingly, when the same reaction conditions were applied to diastereomeric 
β-lactone 2.5’, the reaction proceeded in excellent yield and diastereoselectivity to give 
2.72’ (Scheme 2.15).  Having reached an impasse, the synthetic approach was 
reevaluated to try to circumvent this problematic step. 
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Scheme 2.15 
 
 
 
2.2.2 Modified Retrosynthetic Analysis of (±)-Spongiolactone  
 The modified retrosynthetic analysis toward spongiolactone invoked a late-stage 
NCAL process with racemic aldehyde acid (±)-2.73 (Scheme 2.16).  The required 
aldehyde acid (±)-2.73 would be secured through standard functional group 
manipulations following a challenging SE’ cyclohexenyl zinc addition to α-substituted 
ketone (±)-2.6 with the stereochemical outcome predicated on a chair-like, closed 
transition state arrangement
36, 42
 guided by the cyclohexyl C8-substituent 
(spongiolactone numbering). The tri-substituted, all anti-cyclohexanone (±)-2.6 would 
be accessed through a Michael addition expected to occur anti to the existing γ-
benzyloxymethylene C13-substituent and subsequent protonation/equilibration at C8. α-
Alkylation of enol ether 2.8, derived from 1,3-cyclohexanedione, with benzyloxymethyl 
chloride followed by application of a Stork-Danheiser enone synthesis would deliver 
cyclohexenone (±)-2.7. 
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Scheme 2.16 
 
 
 
 
2.2.3 Development of Consistent Cyclohexenylzinc Reagent Preparation 
 With the desired trisubstituted cyclohexanone (±)-2.6 already in hand, we next 
studied the challenging SE’ addition of cyclohexenyl zinc chloride 2.4 that would install 
two adjacent quaternary carbons including one all-carbon stereocenter.  Initially, efforts 
to consistently form the desired cyclohexenylzinc reagent followed closely to that 
reported by Knochel and coworkers (Table 2.1).
36
  Though the allyl chloride required in 
our efforts toward spongiolactone had not been reported previously, conversion to allyl 
chloride 2.76 from commercially available cyclohexenol 2.75 proceeded in good yield 
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and was used without further purification.  Problems were encountered, however, in the 
conversion from allyl chloride 2.76 to allyl zinc reagent 2.4.  Either the allyl zinc reagent 
would be completely inactive, as determined by titration with iodine as described 
previously,
36
 or the concentrations were <0.01 M and quickly diminished after only a 
few hours (Table 2.1, Entry 1).   
 
Table 2.1 Optimization of allyl zinc reagent preparation.  
 
 
entry 
modification to 
conditions 
Result 
1 - <0.02 M 
2 
Allyl chloride 2.x 
purified 
Inactive 
3 
Allyl chloride 2.x 
freshly prepared 
0.05 M after 15 h 
4 Flame-dried zinc 
Visible activation with only addition of 1,2-
dibromoethane, TMSCl added, inactive 
5 TMSCl excluded 0.06 M, reagent 2.4 stable up to 1 week at -20 ˚C 
 
Initial efforts to overcome these problems focused on allyl chloride 2.76.  Since 
this intermediate is unstable, purification was initially avoided and it was reasoned that 
impurities may be causing problems with the allyl zinc formation, however the results 
did not change when purified 2.76 was used (Entry 2).  Freshly preparing 2.76 (Entry 3) 
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did ultimately yield active allyl zinc reagent 2.4 though the reaction was sluggish and not 
reproducible over several trials.   
Since experimenting with 2.76 did not lead to improvements in preparing the 
allyl zinc reagent, the focus shifted to the zinc itself.  Attempted activation of Zn
0
 
powder with HCl
 
led to no improvement in the reaction.  Flame drying both Zn
0
 and 
LiCl showed promise.  Specifically, it was noted that when the zinc was flame dried 
(Entry 4), activation, indicated by vigorous bubbling, proceeded with only the addition 
of 1,2-dibromoethane, though adding trimethylsilyl chloride (TMSCl) as carried out in 
the literature resulted in inactive reagent.  This led us to question whether the TMSCl 
was truly necessary to effect the desired transformation.  Pleasingly, it was found that 
exclusion of this reagent resulted in consistent preparation of 2.4 (Entry 5) and, further, 
that this reagent was stable for up to a week when stored under nitrogen at low 
temperatures. 
The addition of LiCl was previously shown by Knochel to facilitate zincate 
formation.
38, 43 
 Addition of Me3SiCl has also commonly been employed to assist with 
zincate formation,
44
 however the exclusion of this additive ultimately enabled consistent 
concentrations (0.2-0.5 M in THF) of the targeted (±)-2.4 to be prepared.  However, 
numerous attempts to add (±)-2.4 to ketone (±)-2.6 under a variety of reaction conditions 
were unsuccessful (Table 2.2).  
It was found that changing the number of equivalents of allyl zinc reagent had no 
effect on the outcome of the reaction (Table 2.2). Likewise, varying the overall reaction 
concentration failed to forge the SE’ addition.  Only upon heating the reaction mixture 
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was any addition observed, though the chemoselectivity was lost with SE addition taking 
place at the t-butyl ester (Entry 6). 
 
Table 2.2 Reaction conditions screened toward SE’ addition. 
 
 
entry equiv of 2.4 temperature (°C) [reaction] time (h) Result 
 
1 
     
1.2 -78 0.5 M 2 Rsm 
2 1.2 -20 neat 12 Rsm 
3 1.9 -20 neat 12 Rsm 
4 3.6 over 24 h -78 → 23 0.06 M 18 Rsm 
5 1.2 -78 → 23 0.01 M 24 Rsm 
6 1.2 -78 → 23, 30→ 65 0.2 M 6 double add’n 
 
 
 Following extensive optimization studies, we ultimately found that in situ 
generation of the allyl zinc reagent (±)-2.4 in the presence of ketone (±)-2.6 led to the 
greatest chemoselectivity and conversion.  Under these conditions, using a large excess 
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of zincate, the desired tertiary alcohol (±)-2.74 bearing two vicinal quaternary centers 
was obtained as an inseparable 4:1 mixture of diastereomers in 24-35% yield (Scheme 
2.17).  
Scheme 2.17 
 
 
 
While yields are modest, ketone (±)-2.6 (45-60%) could be easily recovered and 
recycled. Some degree of facial selectivity is anticipated for the major diastereomer of 
(±)-2.6, as shown for one enantiomer of both ketone and zincate, proceeding through 
cyclic transition state A, as previously proposed for related additions to 
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cyclohexanones.
36, 42
  This transition state arrangement predicts the major diastereomer 
for new stereocenters C9 and C10 as shown in alcohol (±)-2.74 which was verified 
following subsequent transformations leading to a crystalline intermediate.   
 Hydrogenation with Pearlman’s catalyst enabled chemoselective reduction of the 
cyclohexene with concomitant hydrogenolysis of the benzyl ether of (±)-2.74 delivering 
a primary alcohol which was directly esterified with isovaleryl chloride to provide ester 
(±)-2.77.  The latter intermediate was crystalline and enabled verification of relative 
stereochemistry by single crystal X-ray analysis.  Conditions to selectively cleave the t-
butyl ester over the isovaleric ester were identified employing TiCl4
45
, and  subsequent 
ozonolysis afforded racemic aldehyde acid (±)-2.73. 
With this aldehyde-acid in hand, we were eager to subject this structurally 
complex substrate to our NCAL methodology.  In situ activation of the carboxylic acid 
with modified Mukaiyama’s reagent24 along with triethylamine as both the nucleophilic 
promoter (Lewis base) and Brønsted base pleasingly provided desired product (±)-2.78  
and its diastereomeric β-lactone (±)-2.78’ in a 3:1 ratio, respectively.  The final step 
toward spongiolactone involved dehydration of tertiary alcohol (±)-2.78.  This was 
accomplished using thionyl chloride to afford spongiolactone (±)-2.1 along with the 
regioisomeric alkene, regio-spongiolactone (±)-2.79 in a ~2.7:1 ratio favoring the more 
substituted alkene found in the natural product (Scheme 2.19).  Characterization data for 
synthetic spongiolactone correlated well with data previously reported for both 
spongiolactone
21 
and nor-spongiolactone.
17  
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2.2.4 NCAL-Based Kinetic Resolution: Accessing (+)-Spongiolactone and 
Derivatives  
We first studied a racemic NCAL involving in situ activation of the carboxylic 
acid with the previously described modified Mukaiyama’s reagent24 using triethylamine 
as both the nucleophilic promoter (Lewis base) and Brønsted base. This enabled 
determination of the inherent diastereoselecitivty of the NCAL with aldehyde acid (±)-
2.73 and provided samples for chiral HPLC analysis.  Under racemic NCAL conditions, 
two β-lactone diastereomers, 2.78 and 2.78’, were produced in modest yield as a 3:1 
mixture of diastereomers (Table 2.3, Entry 1). Commercially available TsCl was also a 
competent activating agent, however modified Mukaiyama’s reagent provided the best 
yields (Entry 2 vs 3).  Premised on our recent success employing isothiourea catalysts 
for the NCAL process with keto acid substrates including homobenzotetramisole 
(HBTM) developed by Birman,
46
 we first studied both optical antipodes of HBTM.  (S)- 
and (R)-HBTM in combination with the modified Mukaiyama’s reagent delivered the 
enantiomeric β-lactones (+)- and (–)-2.78 in 6-16% yields (maximum yield 45% for 
kinetic resolution employing (±)-2.73 with 4:1 dr) in up to 78-84% ee (Entries 4,5) along 
with 12-16% of the diastereomeric β-lactones 2.78’.  Importantly, (R)-HBTM also 
reversed the inherent diastereoselectivity of the substrate (Entry 1 vs 5, 3:1 vs 1:2 dr). 
The enantiopurity of the undesired diastereomeric β-lactone 2.78’ was low (20 % ee) 
with both promoters, however (-)-benzotetramisole (BTM) improved the enantiopurity 
of the undesired diastereomer (+)-2.78’, but did not improve the enantiopurity of (+)-
2.78 (Entry 5).   
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Table 2.3 Optimization of the kinetic resolution via the NCAL process with (±)-2.73.
[a] 
 
 
entry 
Lewis 
base 
yield [%] 
(2.78:2.78’:2.73’)[b] 
dr 
(2.78:2.78’)[c] 
ee [%] 
(2.78)
[d]
 
ee [%] 
(2.78’)[d] 
      
1 Et3N 30:9:ND 3:1 - - 
2
[e] (±)-
HBTM 
10:10:ND 1:1 - - 
3 
(±)-
HBTM 
16:2.5:ND 6:1 - - 
4 
(S)-
HBTM 
16:16:ND 1:1 78
[f]
 20
[f]
 
5 
(R)-
HBTM 
6:12.5:ND 1:2 84 20 
6 (-)-BTM 11:10:ND 1.2:1 81 60 
7 TMSQD 19:14:27 1.3:1 93
[f]
 77
[f]
 
8 TMSQN 10:4:34
[g] 
2.5:1 90 ND 
9
[h] 
TMSQN 10:3:18
[g] 
5:1 92 ND 
10 TMSQN
[i] 
10:<5:25
[g] 
2:1 90 ND 
[a] All reactions were performed under the following conditions: 1.0 equiv nucleophilic promoter, N-nPr-2-bromopyridinium triflate 
(modified Mukaiyama’s reagent, 3.0 equiv), (iPr)2NEt (5.0 equiv), CH2Cl2, 24 h, 23 °C unless noted otherwise. [b] Yields refer to 
isolated purified yields. [c] Diastereomeric ratios determined by integration of 1H NMR (500 MHz) or by isolation of each 
diastereomer (entries 1-3, 8, 9). [d] Enantiomeric excess was determined by chiral phase HPLC.  [e] TsCl (1.5 equiv) was used as the 
activating agent.  [f] Enantiomeric excess for the enantiomeric products, (–)-2.78’ and (–)-2.78’. [g] Yield of 2.78’ estimated from 1H 
NMR (500 MHz) integration.  [h] 2.0 equiv of (iPr)2NEt was used.  [i] 0.27 equiv of catalyst employed. ND = Not Determined. 
 
We next studied Cinchona alkaloid derivatives which had previously proved 
successful with aldehyde acid substrates.
22
 Use of TMSQD (Entry 6) and TMSQN 
(Entry 7) showed marked improvement in enantioselectivity, with both promoters 
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providing ≥ 90% ee in 15-33% yields along with significant quantities of epimerized 
aldehyde (±)-2.73’ (27-34%). Following conversion to the natural product (vide infra), 
we determined, by comparison of optical rotations, that TMSQN generated the 
enantiomer (+)-2.78 required for synthesis of (+)-spongiolactone.  Resubjecting the 
epimerized aldehyde to the NCAL conditions showed that this diastereomer did not 
undergo the NCAL process suggesting that the relative stereochemisty of  β-lactones 
2.78, 2.78’ differed at the β-lactone rather than C14 and this was subsequently confirmed 
by conversion of β-lactone 2.78 to spongiolactone and detailed NMR analysis of (+)-
2.78’ and (±)-2.73’.i Toward minimizing epimerization of the substrate aldehyde (±)-
2.73, the equivalents of Hünig’s base were descreased. This decreased epimerization and 
also improved the diastereoselectivity of the reaction providing a 5:1 dr (Entry 8).  While 
our initial studies made use of a full equivalent of chiral promoter, it should be noted that 
decreasing the catalytic loading to 27 mol% did not decrease the yield nor 
enantioselectivity but did have an impact on diastereoselectivity (Entry 9).  
 
2.3 Conclusion 
In summary, we completed the first total synthesis of (+)-spongiolactone 2.1 in 
11 steps from commercially available 1,3-cyclohexanedione.  The synthesis highlights 
the use of an in situ generated, complex cyclohexenyl zincate for addition to a complex, 
sterically hindered ketone to generate two adjacent quaternary carbon stereocenters, 
including an all-carbon quaternary stereocenter as well as an advanced application of the 
NCAL process.    
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CHAPTER III  
CYTOTOXICITY STUDIES OF (+)-SPONGIOLACTONE AND DERIVATIVES: 
DISCOVERY OF A MORE POTENT, UNNATURAL DERIVATIVE, REGIO, 
BIS-EPI SPONGIOLACTONE 
 
3.1 Introduction 
β-Lactones are effective enzyme acylating agents. Through covalent modification 
of nucleophilic active site residues, they have demonstrated pharmacological relevance 
in their inhibition of fatty acid synthase (FAS) and serine hydrolases.
47
 Specific 
examples include, but are not limited to, orlistat (3.1), omuralide (3.3), and 
salinosporamide A (3.5). 
Orlistat (tetrahydrolipstatin, 3.1) is an FDA approved anti-obesity drug (Figure 
3.1).   Mechanistically, acylation of serine residues in the active sites of pancreatic and 
gastric lipases leads to irreversible inhibition of these enzymes, which are responsible for 
the conversion of triglycerides to absorbable monoglycerols and free fatty acids.  As part 
of a separate screening for prostate cancer inhibitors, orlistat was also found to be a 
novel inhibiter of the thioesterase domain of fatty acid synthase, which plays a role in 
tumor growth progression.
48
  X-ray crystallography confirmed that this inhibition results 
from acylation of the thioesterase molecules via the β-lactone moiety in the active site of 
FAS.
49
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Figure 3.1 Orlistat: a known FAS inhibitor. 
 
Omuralide (clasto lactacystin β-lactone, 3.3), a β-lactone containing small 
molecule active against the 20S proteasome, arises from the natural product lactacystin 
in situ under slightly basic conditions (pH 8) through loss of N-acetylserine (Figure 
3.2).
47
 Mechanistically, omuralide leads to irreversible inhibition by acylation of the N-
terminal threonine in the proteasome. 
 
 
Figure 3.2 Mechanism of inhibition for lactacystin. 
 
 Salinosporamide A (3.5) is a marine natural product, discovered in 2003 by 
Fenical, Jensen and coworkers
50
 that also inhibits the 20S proteasome by forming a 
covalent adduct with an N-terminal threonine (Figure 3.3).  Structurally, the fused γ-
lactam, β-lactone core is the same as that found in omuralide (3.3), however 
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salinosporamide A also contains a chloroethyl side chain, a methyl substituent at the β-
lactone, and a cyclohexene in place of an isopropyl group.  Its inhibitory activity against 
the 20S proteasome is at the nanomolar level and persists for longer than 24 hours.  
Mechanistically, this prolonged inhibition has been found to arise from formation of 
tetrahydrofuran (3.7) by an SN2 displacement of the alkyl chloride by the alcohol that 
comes from the initial opening of the β-lactone (3.5).51 
 
 
Figure 3.3 Inhibition of 20S proteasome by salinosporamide A.   
 
The tetrahydrofuran introduces additional steric bulk around the ester adduct 
between the threonine and salinosporamide A (3.5), effectively blocking its hydrolysis 
and thus reducing reversibility.  Because of its remarkable activity, salinosporamide A 
entered Phase I clinical trials as a candidate to treat multiple myeloma.
52
 
 
3.1.1 Targeted β-lactone Derivatives Based on Synthetic Route to Spongiolactone  
 Given the precedent for β-lactones acting as covalent inhibitors,47 and the 
chemistry developed toward spongiolactone, regio-isomeric, bis-epimeric, and more 
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simplified tricyclic β-lactones were targeted to accompany spongiolactone for biological 
activity testing (Figure 3.4). 
 
 
Figure 3.4 Targeted derivatives for biological activity testing. 
 
All of these compounds could be accessed by chemistries developed toward the 
natural product itself and, in fact, compounds 2.1, 2.79, 2.5, and 2.5’ had already been 
synthesized.  Depending on the observed cytotoxicity of spongiolactone, we 
hypothesized that simplified tricyclic β-lactones 2.5 and 2.5’ could provide insight into 
the pharmacophore which was already thought to be, in part, the β-lactone moiety. 
 
3.1.2 Measuring Cell Viability by the MTT Assay 
When carrying out cytotoxicity studies, it is crucial to have an effective, reliable 
way to quantify the net effect of the compound of interest on cells.  To do this, assays 
are often used where a colorimetric change takes place, brought about by the surviving 
cells.  Tetrazolium salts, which are pale in color, have found great utility on these 
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grounds, given their conversion to vibrant formazens by dehydrogenase enzymes (Figure 
3.5), which are only active in living cells.
53, 54
    The tetrazolium salt 2-(4,5-dimethyl-2-
thiazolyl)-3,5-diphenyl-2H-tetrazolium bromide (MTT) has proved especially useful for 
this application.   The amount of formazen produced directly correlates with the number 
of living cells and the colorimetric assay of the sample can be carried out directly 
without any type of purification or washings.
53
  Further, this method is generalizable 
across cell lines. 
 
 
Figure 3.5 Conversion of MTT to formazen in living cells. 
 
3.2 Results and Discussion 
3.2.1 Synthesis of Derivatives 
 The first additional derivative we targeted was simplified tricyclic β-lactone 3.9 
that would contain the same isovaleric ester side chain that is found in the natural 
product (Scheme 3.1).  Starting from β-lactone 2.5’, hydrogenolysis using Pearlman’s 
catalyst cleanly provided the intermediate primary alcohol, which was immediately 
acylated with isovaleryl chloride to give the isovaleric ester derivative 3.9. 
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Scheme 3.1 
 
 
 
 The second additional derivative synthesized was regioisomeric, bis-epimeric 
spongiolactone.  Utilizing the allyl zinc addition adduct that had been previously 
synthesized in our investigations into the SE’ addition to tricyclic β-lactone 2.5, 
Pearlman’s catalyst was employed to reduce the cyclohexene with concomitant 
hydrogenolysis of the benzyl ether to provide an intermediate primary alcohol (3.13, 
Scheme 3.2) which was immediately acylated with isovaleryl chloride to yield isovaleric 
ester 3.14.  Dehydration with thionyl chloride led to regioisomeric olefin products: 
tetrasubstituted olefin 3.15 and tri-substituted, 6,15-bis-epi-spongiolactone 3.8. 
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Scheme 3.2 
 
 
 
3.2.2 Initial Screening Against Various Cancer Cell Lines  
 Initial screening of (+)-spongiolactone (2.1) and its derivatives was carried out 
against HepG2-hepatocellular carcinoma (liver cancer), A549-lung adenocarcinoma 
(lung cancer), and MCF-7-breast adenocarcinoma (breast cancer) cell lines.
†
  
Disappointingly, no inhibitory activity was observed in of these cell lines, as determined 
by the MTT assay (Figure 3.6).   
 
 
 
 
                                                 
†
 In collaboration with Professor Stephan Sieber and research assistant Dr. Joanna Krysiak at Technische 
Universität München. 
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a. 
 
b. 
 
Figure 3.6 Summary of results for MTT assay conducted against a. liver cancer cells b. 
lung cancer cells and c. breast cancer cells. 
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c. 
 
Figure 3.6 Continued. 
 
Here, it can be seen that even at increased concentrations of the derivatives, the 
% metabolic activity remains relatively constant. 
 
3.2.3 Preliminary Cytotoxicity of Spongiolactone and Derivatives  
 Fortunately, screening of the K562 human myelogenous leukemia cell line, the 
same cell line in which the β-lactone congener of spongiolactone (2.1), nor-
spongiolactone, showed much more promising results specifically for the natural product 
itself as well as the regio-isomeric, bis-epimeric-spongiolactone (3.8),  Interestingly, the 
benzyl ether tricyclic β-lactones (3.9 and 3.10), as well as regio-isomeric spongiolactone 
(2.79), differing only by having a tri-substituted olefin instead of a tetra-substituted 
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olefin showed no inhibition, with IC50 values of >500 μM, even though the presumed 
pharmacaphoric β-lactone is present in all three derivatives (Table 3.1).  These results 
imply that the overall topology of the molecule, which affects the molecule’s ability to 
acylate a specific protein, is highly impacted by the olefin geometry, and that the 
pendant cyclohexane, and all-carbon quaternary center, are critical for achieving 
inhibition. 
 
Table 3.1 IC50 values for (+)-spongiolactone 2.1 and derivatives against the K562 
human chronic myelogenous leukemia cell line.  
 
 
 
 
 
Entry β-lactone[b] IC50 ±
 
SEM (µM)
 [b]
 
1 spongiolactone ((+)-2.1) 129 ± 10 
2
 
regio spongiolactone ((+)-2.79) >500 
3 regio, bis-epi spongiolactone ((±)-3.8) 29 ± 4 
4 benzyl ether (±)-2.5 >500 
5 diastereomeric benzyl ether (±)-2.5‘ >500 
6 isovaleric ester (±)-3.9 297 ± 49 
[a] Optically active material was accessed employing TMSQN as a nucleophilic promoter and simplified β-lactones were accessed by 
aldehyde acid  (±)-2.71. [b] All IC50 values were determined by utilizing a MTT metabolic activity assay. Assays were performed in 
triplicate. SEM = standard error of the mean. 
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 The observed cytotoxicities for 2.1 and 3.8 were shown to be reproducible, with 
2.1 (spongiolactone) having an average IC50 value of 132 μM.  We were intrigued to find 
that the unnatural derivative 3.8 had much higher inhibition, with an average IC50 value 
of 29 μM for a racemic sample.  If we hypothesize that only one enantiomer is leading to 
the observed inhibition, then the IC50 value for the active enantiomer should be much 
lower.  
 
3.3 Conclusion 
 In conclusion, spongiolactone 2.1 and five other novel derivatives were 
submitted for cytotoxicity studies.  The natural product along with its regio-isomeric, 
bis-epimeric analogue showed cytotoxicity against the K562 cell line.  Of note is that the 
IC50 value for the unnatural analogue 3.8 was more potent than the parent natural 
product. 
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CHAPTER IV  
CELLULAR TARGET IDENTIFICATION OF (+)-SPONGIOLACTONE AND 
REGIO, BIS-EPI SPONGIOLACTONE 
 
4.1 Introduction 
Upon identification of bioactive natural products through screening various cell 
lines, it is desirable to identify the specific protein target of the small molecule.  Once 
target identification is complete, the small molecule can be modified to improve activity, 
or, alternatively, to identify other simplified structures that can produce the same effect.  
There are five common strategies employed in cellular target identification, including 
high-throughput screening, phenotype-based approaches,
55, 56
 identification by 
deduction, affinity chromatography, and activity-based protein profiling
55
 (ABPP).  Of 
these, affinity chromatography and ABPP have received considerable attention, with 
both relying on modification of the molecule of interest with a tag and subsequent 
binding to a protein.   
 
4.1.1 Activity-based Protein Profiling (ABPP) and Stable Isotope Labeling by 
Amino Acids in Cell Culture (SILAC) for Cellular Protein Target Identification 
Activity-based protein profiling (ABPP) is used to study enzyme subsets within a 
given proteome.  It relies on covalent modification of an electrophilic, small molecule 
probe by nucleophile addition of an amino acid residue specifically located at or near the 
binding pocket of the molecule within a protein target
57
.  Aside from an electrophilic 
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reactive group, the probe also contains a spacer and a reporter tag.  The reporter tag 
provides a means for a bio-orthogonal coupling reaction,
58
 such as a ‘click’ reaction, 
which involves a copper(I)-catalyzed alkyne-azide [3+2] cycloaddition through a step-
wise modification of the Huisgen triazole synthesis.
59
  In this case, the reporter is a 
terminal alkyne
60
 (Figure 4.1).  The labeled proteome is subjected to click chemistry 
conditions with an azide coupling partner, which contains either a fluorophore or biotin.   
 
 
Figure 4.1 General schematic of ABPP. 
 
Once the triazole is formed, the probe-labeled protein is separated from the 
proteome by either gel electrophoresis (if a fluorophore is present) or by affinity 
separation using streptavidin beads.  The protein(s) can be identified by subsequent 
digestion from the bead followed by mass spectrometry analysis.  While this approach 
has proved effective in target identification, it does not allow the level of inhibition to be 
quantified. 
Stable isotope labeling by amino acids in cell culture (SILAC) is a mass-
spectrometry technique that enables quantitative proteomic analysis through utilizing 
isotopically labeled arginine or lysine (Figure 4.2).
61
 This technique has been coupled 
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with ABPP as a direct and sensitive way to quantify inhibitory effects of small molecule 
probes.   
 
Figure 4.2 Stable isotope labeling by amino acids in cell culture (SILAC) coupled with 
ABPP. 
 
 
 
In this approach, two batches of the cells of interest are grown, where one sample 
will be fed either 
13
C or 
15
N (heavy) labeled amino acids and the other sample will be fed 
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12
C
 
or 
14
N (light) amino acids.  Over several divisions, the amino acids become 
incorporated into the cells.  It should be noted that whether heavy or light amino acids 
are used, there are no behavioral differences between the cells.  Either the light or heavy 
cells are then treated with an inhibitor, while the other is treated with DMSO to serve as 
the control.  A biotinylated probe is then added to both sets of cells and the previously 
described method for ABPP is carried out.  The samples from the different cell media 
are combined and by mass spectrometry the relative protein abundance quantified by 
examining the relative intensities of the two sets of peaks resulting from the isotopically 
labeled samples.  Protein identification is also possible in this approach by peptide 
fragment analysis via MS-MS.
62
  
 
4.1.2 Synthetic Design of an Alkyne-Containing Probe  
In considering the synthetic design of an alkyne-containing probe, it is critical for 
the spacer and alkyne to have a negligible effect on the interaction between the reactive 
group of the probe and the enzyme active site.  Thus, the spacer should not have 
significant steric bulk, impart rigidity, or alter the hydrophobicity/hydrophilicity of the 
compound.   
The reactive group of the probe should be of sufficient electrophilicity such that 
it can undergo nucleophilic attack by amino acid residues such as serine and cysteine.  
Many ubiquitin derivatives have been successful in studying deubiquitinating enzymes
57
 
(Figure 4.3 a).  Other more common electrophiles, such as fluorophosphonates 4.6 have 
demonstrated high specificity for serine hydrolases (Figure 4.3 b), and epoxides, such as 
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natural product E-64 (4.9) have been utilized extensively with cysteine proteases
63
 
(Figure 4.3 c).   
 
 
Figure 4.3 a.) Ubiquitin probes (4.1) for deubiquitinating enzymes, b.) 
fluorophosphonate probes (4.6) for serine hydrolases, and c.) epoxide probes (4.9) for 
cysteine proteases. 
 
 
 
Other reactive groups include Michael acceptors (i.e. α, β-unsaturated carbonyls), 
alkyl halides (such as activated alkyl fluorides), and acylating groups (such as β-lactams 
and β-lactones). 
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4.1.3 β-lactones and ABPP 
 Over the past several years, β-lactones have emerged as effective small 
molecules for labeling enzymes.  With a ring strain of approximately 22.8 kcal/mol, β-
lactones (4.12) display moderate electrophilicity relative to oxetanes (4.13), aziridines 
(4.14), or epoxides (4.15) (Figure 4.4).   
 
 
Figure 4.4 Comparison of ring strains relative to β-lactones. 
 
  In considering an enzyme active site, this modulated reactivity leads to greater 
selectivity for nucleophilic addition of an amino acid residue. The resulting covalent 
adduct is suitable for ABPP studies.   
Not only can libraries of these molecules be prepared in a facile manner, but also 
the selectivity for different enzyme classes can be modulated by varying the R-group 
substituents.  To this end, Sieber and coworkers have demonstrated the remarkable 
ability of relatively simple β-lactones to specifically label a wide variety of enzymes 
within several different families (Figure 4.5).
64
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Figure 4.5 Application of β-lactone library to ABPP. 
 
Through synthesis of a β-lactone library, and applying the ABPP technique, over 
twenty different enzymes were labeled from four major families.    
 
4.2 Results and Discussion 
4.2.1 Total Synthesis of an Alkynyl Regio, bis-epi Spongiolactone Probe 
Due to their complex scaffolds, which often translate into selectivity among 
different enzyme classes, natural products containing an electrophilic moiety are 
particularly appealing.  However, installation of an alkyne onto a natural product for 
subsequent bio-orthogonal reactions can be a challenging task.
65
  The natural product 
must either contain a functional group that is amenable to modification, or alternatively, 
the parent structure must be modified to enable the desired transformation. Such 
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structural revisions are often accessible through an established total synthesis.  Given the 
demonstrated ability of simplified β-lactones to selectively label enzymes,66-68 we were 
encouraged to pursue the synthesis of an alkyne-containing probe derivative from 
spongiolactone through only minor modifications to our established synthetic route to 
the natural product.   
In considering the design of an alkyne probe derived from regio, bis-epi 
spongiolactone, we identified the pendant ester to be an ideal point of modification.  
Here, alkyne probe 4.16 would come from dehydration of tertiary alcohol 4.17 that could 
arise from esterification of preceding primary alcohol 4.18 which is easily accessible 
based on our established synthetic work (Scheme 4.1). 
 
Scheme 4.1 
 
 
 
 To this end, primary alcohol 3.13 was treated under modified Steglich 
esterification conditions with 5-hexynoic acid to afford alkynyl ester 4.17 (Scheme 4.2). 
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This alkynyl acid was selected based on its moderate chain length and commercial 
availability.  Subsequent dehydration provided 4.16 as an initial probe for ABPP studies. 
 
Scheme 4.2 
 
 
 
4.2.2. Verifying Cytotoxicity of Probes Through Cell Based Assays: MTT 
 Once a probe is synthesized, it is critical to confirm that this new derivative 
maintains the bioactivity observed for the parent compound.  Ideally, the modification is 
not near the pharmacaphore and the activity remains nearly the same, if not the same. To 
this end, alkynyl probe 4.16 was used to treat K562 cells and the outcome evaluated by 
the MTT assay.   
 From this assay, run as a side-by-side comparison with 3.8, we were pleased to 
find no significant change in cytotoxicity, with the probe having an IC50 value of 32.3 
μM compared to 39.8 μM observed for parent compound 3.8.  
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4.2.3 Preliminary labeling studies toward ABPP  
 Alkyne probe 4.16 was utilized in the SILAC experiment of K562 cells (Figure 
4.6).  Here, we are looking for the appearance of new bands that have been treated with 
the probe versus the control cells which have only been treated with DMSO.  From these 
experiments, 4 new bands appeared which were excised and analyzed by mass 
spectrometry to try to identify proteins specifically labeled by the probe (25, 40, 32, 98 
kDa).      
 
Figure 4.6 Gel from ABPP of K562 cells using alkynyl probe 4.16. 
 
From each band, a list of protein candidates was compiled including, but not 
limited to very-long-chain 3-oxoacyl-CoA reductase, heterogeneous nuclear 
ribonucleoprotein A0, ATP-dependent 6-phosphofructokinase, platelet type, casein 
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kinase II subunit beta, and heme oxygenase 2.  Heme oxygenase 2 was one of the most 
intense bands observed.  Further analysis is necessary to determine if this particular 
protein is a logical target for a β-lactone, given their typically observed inhibition by 
acylation. 
 
4.3 Conclusion 
 Alkynyl probe 4.16 was successfully synthesized to be used in ABPP for target 
identification.  Based on an MTT assay run in parallel with the parent compound of 
interest, no loss in cytotoxicity was observed against the K562 cell line.  Further, 
preliminary ABPP with SILAC experiments showed the appearance of 4 unique bands 
which have been analyzed by mass spectrometry to compile a list of potential protein 
targets.  Further experimentation is necessary to complete these studies. 
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CHAPTER V  
RECYCLABLE ISOTHIOUREA CATALYSTS 
 
5.1 Introduction 
 Organocatalysis can be defined as an acceleration brought about by the 
substoichiometric addition of an organic compound to a given reaction.
69
  Described as 
the ‘golden age’ of organocatalysis, from 2004-2005, over 500 publications specifically 
addressing stereoselective organocatalysis appeared in the literature
70
 and since this 
time, the remarkable potential of this field continues to be demonstrated.  While more 
advancements in transformations amenable to organocatalysis are being developed, there 
are still areas for improvement.   
For example, the bar for increasingly lower catalytic loading continues to be 
raised as the catalysts themselves are often costly.  Further, separation of the 
organocatalyst from the reaction product can often be tedious.  To overcome cost and 
purification limitations, many chemists have turned to supported organocatalyst systems.  
Such developments seek catalyst recyclability, where the organocatalyst is able to be 
both recovered from the reaction and, subsequently, reused. 
 
5.1.1 Immobilizing Organocatalysts: Solid versus Soluble Supports 
 Since the seminal report of solid-phase peptide synthesis (SPPS) by Merrifield in 
1963,
71
 work that earned him the Nobel Prize in Chemistry in 1984, the breadth of 
supported systems in chemical synthesis continues to grow.  In Merrifield’s approach, an 
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amino acid is covalently attached to a resin, the peptide chain is grown, and cleavage of 
the original linkage provides the free polypeptide 5.5 (Scheme 5.1).  
 
Scheme 5.1 
 
 
 
A few years later, Letsinger and coworkers applied a similar strategy to 
oligodeoxyribonucleotides with a styrene based, insoluble polymer as the support.
72
  
Inspired by this approach, much of the early work in catalyst supports utilized insoluble 
supports.   In fact, the first example of supported chiral ligands by Kagan and co-
workers
73
 utilized cross-linked polystyrene beads (Merrifield resin) in the asymmetric, 
catalytic reduction of ketones.  The use of solid supports was appealing as it allowed the 
catalyst to be separated from the reaction medium by simple filtration, but was limited in 
that the behavior of the immobilized, heterogeneous catalyst typically performed 
inferiorly to the free, homogeneous catalyst; an observation largely attributed to blocked 
active sites by the support itself.
74
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 In an effort to achieve both excellent catalyst behavior and facile separation, 
Bayer and Mutter developed the first example of a chiral ligand attached to a soluble 
polymer
75
 which they used in the asymmetric hydroformylation of styrene.  Initially 
focusing on linear polystyrene as the soluble support, their work was later extended to 
include polyacrylonitrile, and poly-(ethyleniminodiacetic acid), polyethylenimine, and 
poly(vinylpyrrolidinone) to chelate metal catalysts.
76
  Still, much of the early work 
utilizing soluble polymer supports faced problems in catalyst behavior and recovery.
77
 
This was observed by Bayer and coworkers in their hydrogenation work,
76
 where the 
reaction times were 30-50% longer and isolation of the supported catalyst had to be done 
by either emulsion or ultrafiltration.  In the time that has passed since these early reports 
of solid and soluble supported chemistries, many improvements have been made in both 
areas providing useful tools for recovering and reusing organocatalysts. 
 
5.1.2 Magnetic Nanoparticles (MNPs) as Solid Supports for Organocatalysts 
 As an attempt to achieve the best of both worlds in supported organocatalysts, 
namely the facile separation of solid supports and increased reactivity of organocatalysts 
on soluble supports, magnetic nanoparticles have emerged as pseudo-heterogeneous 
supports.
74
 Here, the supported organocatalyst is easily separated by applying an external 
magnet, avoiding the need for filtration or centrifugation as is typical in other solid 
supported systems. Additionally, when well-dispersed in the reaction media, their high 
surface area allows them to behave similarly to the soluble free catalyst.  
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 The magnetic nanoparticles (MNPs) used for organocatalysts may be metal based 
(i. e. Ni, Fe, or Co), metal oxides (MnFe2O4, CoFe2O4, CuFe2O4, and Fe3O4), or alloys 
(CoPt3, CoFe, or FePt).
78
  While each type of nanoparticles has been successfully 
employed as organocatalyst supports, magnetite (Fe3O4) has emerged as an exceptionally 
useful support.  Not only is the synthesis of magnetite cheap and facile, but it also is 
nontoxic and inert under a variety of conditions.
79
 
 The organocatalyst itself can either be attached to the MNP by a linker or directly 
to the surface.  Organosilicon linkers are especially popular, where a silica shell is 
formed on the surface of the magnetite by using tetraethoxysilane 5.6 and subsequent 
treatment with a functionalized triethoxysilane 5.7 provides a terminal functional group 
onto which the organocatalyst can attach (Scheme 5.2).
80
 
 
Scheme 5.2 
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 If instead direct attachment is desired, the organocatalyst must contain, either 
inherently or through derivatization, an appropriate functional group that will adhere to 
the magnetite surface.  Catechol has been found to adhere strongly to the surface, 
making dopamine a commonly used linker for organocatalyst attachment.
81
  Connon and 
coworkers utilized dopamine to develop the first magnetic nanoparticle supported chiral 
DMAP analogue (Scheme 5.3).
82
 This catalyst was able to be recycled up to 30 times in 
the acylation of racemic sec-alcohols. 
 
Scheme 5.3 
 
 
 
Likewise, phosphonic acids are a stable means of attachment and, like dopamine, 
can be adsorbed onto the surface of magnetite (Scheme 5.4).
83
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Scheme 5.4 
 
 
 
In this example, the phosphonic acid 5.15 was revealed from the corresponding 
phosphonate ester 5.14 and allowed the cinchonidine-derived organocatalyst to be 
attached to the MNP. This catalyst system was applied in the asymmetric aldol reaction 
and could be recycled up to seven times. 
Terminal carboxylic acids have also been used,
84
 though this linker is less robust 
and more sensitive to the pH of the reaction medium.  For example, amino acids such as 
arginine have been adsorbed onto magnetite directly and applied to the synthesis of 
chromenes, though the recyclability was limited to four cycles (Scheme 5.5). 
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Scheme 5.5 
 
 
 
 MNPs have proven successful in the area of organocatalyst supports, though they 
are not always inert in reactions and, in some cases, even coating the surface with 
siloxanes does not prevent a background reaction from taking place.
85
    
   
5.1.3 Polyisobutylene (PIB) as a Soluble Polymer Support for Organocatalysts 
 In the realm of soluble polymer supports, poly(alkene)oxide (PEG) has been used 
extensively.
86
 However, while successful in serving as a support for a variety of 
catalysts, there are several limitations in using this polymer including solubility issues 
(the catalyst-supported systems are only completely soluble above 75 ˚C in nonpolar 
solvents and minimally soluble at any temperature less than 50 ˚C).87  Considering that 
the vast majority of catalysts are used to carry out stereoselective reactions, which are 
often run at temperatures below 0 ˚C, PEG is not a viable option for a soluble polymer 
support. 
 PIB provides an alternative to PEG without the temperature-dependent solubility 
limitations.
88
  Further, PIB provides excellent phase discrimination between polar and 
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non-polar solvents, making its recovery facile, and standard functional group 
interconversions of the terminal olefin allow this support to be tailored to accommodate 
a variety of nucleophiles as linkers to the catalyst (Scheme 5.6). 
 
Scheme 5.6 
 
 
 
5.1.4 Utility of Isothiourea Catalysts in Organic Transformations 
Amidine bases have long been used in organic synthesis.  Though classically it is 
taught that common amidines, such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 
1,5-diazabicyclo[4.3.0]non-5-ene (DBN) are non-nucleophilic bases, studies in 
organocatalysis have only recently uncovered the value of these systems as nucleophiles 
attributed to charge delocalization between the two nitrogen atoms.
89
  Through probing 
the ability of various amidine systems to catalyze the acylation of simple alcohols, 
Birman and coworkers concluded that the size of the ring system impacted reactivity:  
DBU (5.29, a 7-6 bicyclic system) was ineffective in affording the desired 
transformation while DBN (5.30, a 6-5 system) worked well (Scheme 5.7).
90
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Scheme 5.7 
 
 
 
With this information, they embarked on exploring a variety of ring sizes for 
amidine systems and isothioureas (Scheme 5.8). At the same time, Okamoto et al were 
also investigating similar modifications.
91
   
 
Scheme 5.8 
 
 
 
Ultimately, they arrived at benzotetramisole (BTM, 5.36), which displayed 
superior selectivity in the kinetic resolution of secondary alcohols.  Here, selectivity is a 
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measure of the ratio of reaction rates for each enantiomer of a given substrate.
92
  It is 
calculated as s = ln[(1-eesm)(1-c)]/ln[(1+eesm)(1-c)] where the conversion is defined as c 
= eesm/(eesm + eepr).   
Since the development of BTM (5.36), homobenzotetramisole (HBTM, 5.38) has 
also been introduced as an acylation catalyst for the kinetic resolution of aryl 
cycloalkanols (Scheme 5.9).
46
   
 
Scheme 5.9 
 
 
 
HBTM displayed greater activity than standard amidine systems which is 
attributed to added stabilization from the σ* of the sulfur atom with a nonbonding pair of 
electrons from the oxygen of the acylammonium.
93
  Since its first introduction, various 
derivatives have been prepared,
94 ,95
 that, along with HBTM itself, have been 
popularized in kinetic resolutions of secondary alcohols,
96
 β-lactams,97 annulation 
processes,
98
 and formal [4 + 2] cycloadditions.
99
  Further, these catalysts have seen 
extensive applications in acylammonium/ammonium enolate chemistry with new 
methodology that is fluorishing in the Romo group.
29
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While HBTM and derivatives are excellent catalysts to achieve high 
enantioselectivity, a few disadvantages include solubility issues which limit reaction 
conditions, as well as their preparation, where attaining enantiopure material is costly.  
Though in theory the cost can be mitigated through catalyst recovery, it has proven very 
difficult to achieve experimentally.  To circumvent these problems, use of an 
organocatalyst support is a viable option.   
 
5.2 Results and Discussion 
5.2.1 Synthesis of Magnetite-supported BTM 
 Based on the known preparation of benzotetramisole (Scheme 5.10), we 
recognized that either the 2-chlorobenzothiazole 5.41 or amino alcohol 5.40 would have 
to be modified.  
 
Scheme 5.10 
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  Due to concerns that modification of the benzothiazole portion of the catalyst 
may alter its behavior, efforts were focused on modifying the amino alcohol.  
Fortunately, phenolic amino alcohol 5.43 is a known compound and was used as the 
starting material for our synthesis (Scheme 5.11).
100
  
 Desiring to utilize phosphonic acid groups to adsorb onto the magnetite, we used 
known bromo-phosphonate ester 5.44
101
 as an electrophile for the phenol.  This reaction 
proceeded cleanly and was taken on directly to the boc-deprotection to provide free 
amino alcohol 5.45.  
 
Scheme 5.11 
 
 
 
Amino alcohol 5.45 was then subjected to an SNAr reaction with 2-
chlorobenzothiazole 5.41 to give 5.46.  Subsequent mesylation of the primary alcohol 
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followed by cyclization gave phosphonate ester BTM derivative 5.47 for the first time.  
Since it is necessary to have the phosphonic acid instead of the phosphonate ester to 
enable adsorption onto the magnetite surface, the ethyl ester had to be cleaved.  Here, 
trimethylsilyl bromide was found to be a suitable reagent to carry out this transformation 
and give the terminal phosphonic acid 5.48. 
 With the catalyst in hand, we turned our efforts to adsorption onto the magnetite 
surface.  The standard approach is to either sonicate or reflux a solution of the catalyst in 
the presence of magnetite.
82, 83
  To this end, simple sonication (Scheme 5.12) in 
methanol provided the adsorbed catalyst 5.49 which was confirmed by IR spectroscopy, 
showing both the key stretches of the BTM catalyst (1612, 1570, and 1466 cm
-1
) as well 
as the phosphonic acid adsorbed onto the magnetite (2600 cm
-1
).   
 
Scheme 5.12 
 
 
 
Further, transmission electron microscopy (TEM) was employed to analyze 5.49 
(Figure 5.1).  Here, one can observe the magnetite core (larger than 8 nm in size) and a 
thin shell (~1 nm thick) on the surface which represents the adsorbed catalyst.   
 
 77 
 
 
Figure 5.1 TEM image of phosphonic acid-(+)-BTM adsorbed on magnetite. 
 
The loading of the catalyst onto the MNP was determined to be 0.067 mmol 
catalyst/1 g of sample by quantitative 
31
P NMR spectroscopy.  Having confirmed and 
quantified the catalyst loading onto the MNP, it was time to study its behavior relative to 
the parent, soluble (+)-BTM catalyst.  We focused on the kinetic resolution of secondary 
alcohols; a reaction in which (+)-BTM is known to perform well.  We chose 1-
naphthylethanol as a starting substrate, as (+)-BTM is known to resolve this alcohol with 
high selectivity in under 12 hours (Table 5.1, Entry 1), and screened (+)-BTM, 
phosphonate ester 5.48, and the absorbed catalyst 5.49.
96
 
In our hands, we found the best result for (+)-BTM to be achieved by Entry 3, 
stopping the reaction at 6 hours achieving a selectivity of 148.  With the baseline 
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established for the homogeneous catalyst, prepared phosphonate ester derivative 5.48 
was next put to the test.  Under reaction conditions identical to Entry 3, 5.48 did not 
perform as well as the parent catalyst, however it should be noted that these conditions 
were not optimized for the new catalyst and that easily separable ester 5.51 was still able 
to be achieved in excellent enantioselectivity (Entry 4). 
 Next, we began our studies on the adsorbed catalyst 5.49.  Running the reaction 
in chloroform formed ester 5.51 in excellent enantiomeric excess (Entry 6, 94%), 
however the conversion was still only 15% over 18 hours.  Extending the reaction time 
led to negligible improvements in conversion up to 40 hours.  In an effort to overcome 
the sluggishness of the reaction, the catalytic loading was increased from 8 mol% to 20 
mol%, however there was no improvement in conversion (Entry 7).  Raising the catalyst 
loading further to 30 mol% saw a slightly faster conversion (Entry 8), but further 
increases to 40 mol% (Entry 9) and 100 mol% (Entry 10) gave no further improvements, 
with 100 mol% catalyst failing to give any conversion.  At this point, the amount of 
loaded MNP required to achieve such high catalytic loadings resulted in a thick slurry, 
making the reaction medium difficult to stir and, ultimately, magnetic decantation highly 
impractical. 
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Table 5.1 Summary of kinetic resolution studies of 1-naphthylethanol with 5.49. 
 
 
entry cat (mol%) time (h) solvent ee5.50 (%) ee5.51 (%) c s 
1* 5.36 (4) 9 PhMe - - 49 128 
2 5.36  (4) 8 CHCl3 80 99 55 49 
3 5.36 (4) 6 PhMe 44 97 31 148 
4 5.36 (4) 8 PhMe 59 97 38 96 
5 5.48 (4) 3 PhMe 50 94 35 44 
6 5.49 (8) 18 CHCl3 17 94 15 63 
7 5.49 (20) 18 PhMe 13 93 12 48 
8   5.49 (30) 7.5 PhMe 13 93 12 48 
9 5.49 (40) 20 PhMe 20 92 18 26 
10 5.49 (100) 81 PhMe 0 N/A 0 N/A 
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Table 5.1 Continued. 
 
entry 
 
cat (mol%) 
 
time (h) 
 
Solvent 
 
ee5.50 (%) 
 
ee5.51 (%) 
 
c 
 
s 
11 
5.48 (4) + 
mnp 
3 PhMe 30 95 24 52 
12 
5.48 (4) + 
mnp 
9 PhMe 43 93 32 33 
13 
5.48 (4) + 
mnp 
18 PhMe 58 92 39 37 
*Reported results from literature;96 ee5.50 and ee5.51 not reported.   
 
While 5.49 did provide enantioenriched ester 5.51, we sought to understand what 
was limiting the reaction conversion.  To test whether the nanoparticles themselves were 
playing a role in hindering the reaction, free phosphonate ester was used in the presence 
of bare magnetite.  The amount of magnetite added was equal to the amount of 5.51 that 
would have been added on the same reaction scale.  After 3 hours, the observed results 
(Entry 11) were nearly identical to 5.48 (Entry 5), though even at this point the 
conversion was lower.  Allowing the reaction to proceed for longer showed the rate of 
conversion and selectivity dropping off significantly (Entries 12 and 13).  The 
conversion did not increase further after 18 h. 
 These crude results seem to point to an interaction taking place between the 
catalyst and the MNP, especially considering the results with the bare MNP (Entries 11-
13) where the reaction initially proceeds the same as the free catalyst 5.48 but then the 
reactivity diminishes.  One possibility is that the catalyst is deactivated by free hydroxyls 
on the MNP surface (Scheme 5.13).  Similar deactivation has been reported for (+)-BTM 
in the presence of moisture during the kinetic resolution of secondary alcohols.
96
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Scheme 5.13 
 
 
 
 Unable to push the reaction to a useful conversion, and with the seemingly 
detrimental effect of magnetite on the reaction, the focus was switched from a solid-
supported catalyst to a soluble, polymer-supported catalyst.  Specifically, we turned our 
efforts to synthesizing a polyisobutylene (PIB) derivative of (+)-BTM. 
 
5.2.2 Synthesis of PIB-supported BTM 
 Beginning with phenol 5.43, alkylation with previously prepared PIB-bromide
88
 
in the presence of tetrabutylammonium bromide (TBABr) as a phase transfer catalyst 
provided sufficient quantities of PIB-phenol 5.56 (Scheme 5.14).  Boc-deprotection 
mediated by 4N hydrochloric acid in 1,4-dioxane proceeded quantitatively and the 
resulting amino alcohol hydrochloride salt 5.57 was taken on directly to the SNAr 
reaction with 2-chlorobenzothiazole 5.41.  Mesylation of primary alcohol 5.58 followed 
by cyclization provided PIB-(+)-BTM derivative 5.59.    
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Scheme 5.14 
 
 
 
 With the PIB-(+)-BTM catalyst 5.59 in hand, we first sought to measure its 
behavior relative to parent catalyst (+)-BTM 5.36 in the kinetic resolution of secondary 
alcohols (Table 5.2).   
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Table 5.2 Initial studies of 5.59 for kinetic resolution of 1-(1-naphthyl)ethanol 5.50. 
 
 
 
entry time (h) ee5.50 (%) ee5.51 (%) c s 
1 7.5 56 94 37 74 
2 4 99 81 55 49 
3 2.5 92 90 50 79 
4* 2.5 97 88 52 76 
*Na2SO4 excluded from reaction. 
 
 Though overall the selectivity for 5.59 was inferior to 5.36, the reaction was 
much faster, reaching 50% conversion in only 2.5 hours (Entry 3).  Further, both 
secondary alcohol 5.50 and ester 5.51 were achieved in excellent enantioselectivity.  
These two adducts are easily separable. 
 Having confirmed that 5.59 is a competent catalyst, studies turned to 
recoverability and recyclability.  Initial attempts to use a biphasic solvent system of 
heptane and acetonitrile effectively separated the catalyst from starting alcohol 5.50, 
however, given that 5.51 is highly nonpolar, a mixture of this product and the catalyst 
was attained in the heptane layer.  Switching to DMF as the polar organic solvent 
showed the same results.  During this experimentation, it was observed that if the 
reaction was directly concentrated and acetonitrile was added, 5.59 formed a separate 
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film that could be washed further with acetonitrile to give the catalyst.  Unfortunately, 
even with these results, the highest recovery was 76%.   
Toward recycling the catalyst, initial results were disappointing and gave very 
low conversion even after extended reaction time (Table 5.3, Entry 1).  Here, recovered 
5.59 was used directly.  Reasoning that it may be necessary to account for the fact that 
the isolated catalyst was isolated as a salt from the reaction, the amount of Hünig’s base 
was increased to 1.5 equiv (Entry 2).  This dramatically improved the conversion, 
however the selectivity was still significantly less than the originally used 5.59 (s= 79), 
pointing to a significant background reaction taking place in the presence of excess base.  
Free-basing 5.59 prior to subjecting it to the reaction showed a reasonable rate of 
conversion though the selectivity was still low (Entry 3).    
 
Table 5.3 Recyclability studies of 5.59 for kinetic resolution of secondary 1-(1-
naphthyl)ethanol (5.50). 
 
 
entry time (h) treatment of 5.59 DIPEA (equiv) ee5.50 (%) ee5.51 (%) C s 
1 16 - 0.75 4 92 4 51 
2 4 - 1.5 64 92 41 47 
3 2 free-base (DIPEA) 0.75 40 92 30 43 
4 2 MeOH quench 0.75 48 92 34 46 
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Quenching the reaction with methanol, as is typically done in other kinetic 
resolution reactions,
96
 did not lead to any improvement in recovery (62%) nor did it lead 
to improved catalyst behavior.   
 
5.3 Conclusion 
 Benzotetramisole (BTM, 5.36) was successfully adsorbed onto the surface of 
magnetite nanoparticles through synthesis of phosphonic acid derivative 5.48.  This 
marks the first isothiourea catalyst to be adsorbed to the magnetite surface.  While the 
formed adduct was able to catalyze the kinetic resolution of secondary alcohol 5.50, the 
highest selectivity achieved was 59 with 24% conversion.  Due to separate experiments 
that pointed to catalyst deactivation taking place in the presence of the nanoparticles, the 
approach to recycling 5.36 was switched from a solid-supported magnetite catalyst to a 
soluble, PIB-supported catalyst.   
PIB derivative 5.59 was successfully synthesized and showed good selectivity 
and conversion in the kinetic resolution of 5.50.  The most recent studies have examined 
recoverability and recyclability of this system.  Further optimization is required in both 
of these areas.  It should also be noted for both the magnetite derivative 5.49 as well as 
PIB-derivative 5.59 other reactions may be more suitable for these catalyst systems 
beyond the kinetic resolution of secondary alcohols. 
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CHAPTER VI  
CONCLUSIONS 
 
6.1 Total Synthesis of (+)-Spongiolactone and Subsequent Bioactivity Studies 
 
 The first total synthesis of (+)-spongiolactone was completed in 11 steps starting 
from commercially available 1,3 cyclohexanedione.  The synthetic route featured a late-
stage nucleophile-catalyzed aldol lacontization (NCAL) reaction on a highly advanced 
aldehyde acid substrate.  Further, a novel allyl zinc reagent was developed to forge a 
challenging all-carbon quaternary center adjacent to a tertiary alcohol.  This key 
transformation required the development of a one-pot protocol for the desired SE’ 
reaction on a tri-substituted cyclohexanone, pushing the limits for this type of addition 
with respect to substrate complexity. 
 Along with the natural product itself, five additional derivatives were prepared 
by modified chemistries developed in the total synthesis.  Once the derivatives were 
prepared, various cancer cell lines were screened, with inhibitory activity observed for 
the K562 cell line.  Most notable from this work was the discovery of a novel 
regioisomeric, bis-epimeric derivative more potent than spongiolactone itself.  This 
derivative was used to form a biological probe containing a terminal alkyne that is being 
used in activity based protein profiling (ABPP) experiments. 
 
6.2 Synthesis and Initial Studies of Supported-BTM Catalysts 
 Toward rendering isothiourea catalysts, namely benzotetramisole (BTM) 
recyclable, both a solid-supported, magnetite adduct as well as a soluble-supported, 
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polyisobutylene adduct were synthesized.  Both displayed reasonable selectivity relative 
to the parent BTM catalyst, with the PIB-BTM catalyst performing superior to the 
magnetite system.  Given this, along with experiments which suggest catalyst 
deactivation with magnetite, studies were directed toward the polymeric system. 
 Here, reaction conversion was faster than BTM with overall good selectivity.  
Improvements are still necessary regarding both recoverability and recyclability.  Lastly, 
other transformations beyond the kinetic resolution of secondary alcohols should be 
explored to test the generality of the PIB catalyst and to see if better recyclability can be 
achieved. 
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APPENDIX A 
EXPERIMENTAL PROCEDURES 
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General Procedures 
All reactions were completed under a nitrogen atmosphere in oven-dried glassware unless 
indicated otherwise.  N, N- Dimethylformamide was dried over activated molecular sieves (4 Ǻ).  
Dichloromethane was dried by passage through alumina or activated molecular sieves (MBraun 
solvent purification system).  Tetrahydrofuran was freshly distilled over sodium and 
benzophenone.  Methanol was freshly distilled from magnesium turnings.  Triethylamine, 
Hünig’s base, diisopropyl amine, and trimethylsilyl chloride were distilled from calcium hydride.  
Cerium chloride heptahydrate was flame-dried under vacuum.  Commercially available reagents 
were used as received.  Zinc powder was purchased from Strem Inc. (99.9%).  
1
H NMR were 
measured at 500 MHz and chemical shifts are reported as δ values in ppm relative to CDCl3 
(7.26 ppm,), coupling constants (J) are reported in Hertz (Hz), and multiplicity follows normal 
convention: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; ddd, doublet of 
doublet of doublets; dddd, doublet of doublet of doublet of doublets; dt, doublet of triplets; dq, 
doublet of quartets; ddq, doublet of doublet of quartets; ABq, AB quartet; m, multiplet; bs, broad 
singlet (prefix app indicates ‘apparent’).  13C NMR were measured at 125 MHz with 
deuterochloroform (CDCl3) as the internal standard (77.16 ppm) for all 
13
C spectra.  Flash 
column chromatography was performed using 60Ǻ silica gel (Silicycle, 230-400 mesh).  Mass 
spectra (ESI) were obtained at the Center for Chemical Characterization and Analysis (Texas 
A&M University).  Optical rotations were recorded on a polarimeter at 589 nm employing a 25 
mm cell.  High performance liquid chromatography (HPLC) was performed using 25 cm chiral 
columns as indicated.  Thin layer chromatography was performed using glass-backed 60Ǻ silica 
gel F-254 (Silicycle, 250 µm thickness).  Developed plates were visualized by immersion in 
ceric ammonium molybdate stain followed by heating.  Infrared spectra were obtained on a FTIR 
spectrometer as a thin film on NaCl plates.  Transmission electron microscopy (TEM) was 
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obtained by the Microscopy and Imaging Center at Texas A&M University utilizing a JEOL 
2010 and micrographs were recorded at medium range magnification (71-145 kX).  X-ray 
diffraction was obtained by the X-ray Diffraction Laboratory at Texas A&M University.   
 
β-Keto enol ether 2.8.  To a solution of 1,3-cyclohexanedione (12.0 g, 107 mmol, 1.0 equiv)  in 
N, N- dimethylformamide (200 mL) was added K2CO3 (17.6 g, 127 mmol, 1.2 equiv).  The 
heterogeneous solution was stirred for 10 min, resulting in a bright orange solution.  Tert-butyl 
acrylate (18.4 mL, 127 mmol, 1.2 equiv) was added dropwise and the reaction was heated to 100 
°C with stirring for 10 h.  The reaction was then cooled to ambient temperature (23 °C) and a 
second portion of K2CO3 (17.6 g, 127 mmol, 1.2 equiv) was added followed by Me2SO4 (12.0 
mL, 127 mmol, 1.2 equiv).  Upon completion of the reaction, as indicated by TLC, quenching 
with pH 7 buffer solution (200 mL) gave a homogeneous solution which was extracted with 
EtOAc (3 x 200 mL).  The combined organic layers were washed sequentially with water (2 x 
200 mL) and brine (200 mL), dried with Na2SO4 and concentrated in vacuo.  The resulting dark 
brown, viscous oil was purified by filtration through a silica plug (SiO2 30 → 60% 
EtOAc/hexanes) to give 24.5 g (90%) of β-keto enol ether 2.8.  TLC (EtOAc:hexanes, 1:1 v/v): 
Rf  = 0.5; 
1
H NMR (500 MHz, CDCl3): δ 3.78 (s, 3H), 2.53 (dt, J = 14.5, 6.0, Hz, 4H), 2.30 (t, J 
= 6.0 Hz, 2H), 2.21 (t, J = 8.5 Hz, 2H), 1.96 (quintet, J = 6.5 Hz, 2H), 1.40 (s, 9H); 
13
C NMR 
(125 MHz; CDCl3): δ 197.3, 172.6, 172.3, 117.5, 79.3, 54.8, 36.0, 33.9, 27.8 (3), 24.5, 20.5, 
17.3; IR (thin film): 3271, 2978, 1729, 1649, 1616, 1371, 1163, 1089 cm
-1
; HRMS (+ESI) m/z 
calcd for C14H22LiO4 [M + Li]
+
: 261.1678, found: 261.1683.  
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Benzyl ether 2.70.  In a flame-dried round-bottomed flask, a solution of diisopropyl amine (4.3 
mL, 30.5 mmol, 1.55 equiv) was prepared in THF (20 mL).  The solution was cooled to 0 °C 
followed by dropwise addition of nBuLi (18.3 mL, 29.4 mmol, 1.49 equiv).  Stirring continued 
for 30 min before cooling to -78 °C.  A solution of 2.8 (5.0 g, 19.7 mmol, 1.0 equiv) in THF (10 
mL) was added dropwise via syringe pump over 1 h.  After stirring for an additional hour at -78 
°C, benzyl chloromethyl ether (5.45 mL, 39.3 mmol, 2.0 equiv) was added neat, dropwise via 
plastic syringe.  The reaction was warmed to ambient temperature (23 °C) and stirred for 12 h.  
Quenching was done at 0 °C with saturated NH4Cl (20 mL).  The organic phase was separated 
and the aqueous layer was further extracted with EtOAc (3 x 30 mL).  The combined organic 
layers were washed with brine (60 mL), dried with Na2SO4, and concentrated in vacuo.  
Purification by flash column chromatography (SiO2 0 → 50% EtOAc/hexanes) gave 5.13 g 
(70%) of benzyl ether 2.70 as a yellow oil: TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.4 ; 
1
H NMR 
(500 MHz, CDCl3): δ  7.37-7.30  (m, 5H), 4.52, 4.50 (ABq, JAB =12 Hz, 2H), 3.89 (dd, J = 10.0, 
4.5 Hz, 1H), 3.79 (s, 3H), 3.57 (app t, J = 9.0 Hz, 1H), 2.66 (dt, J = 18.0, 5.0 Hz, 1H), 2.55-2.46 
(m, 4H), 2.29-2.20 (m, 3H), 1.89-1.81 (m, 1H), 1.41 (s, 9H); 
13
C NMR (125 MHz; CDCl3): δ 
197.1, 172.8, 172.0, 138.3, 128.2 (2), 127.54, 127.47, 127.4, 117.5, 79.5, 73.1, 69.7, 54.9, 44.8, 
34.1, 28.0 (3), 23.9, 23.7, 17.8;  IR (thin film): 3061, 3031, 2931, 1723, 1613, 1154 cm
-1
; HRMS 
(+ESI) m/z calcd for C22H31O5 [M + H]
+
: 375.2171, found: 375.2176. 
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Cyclohexenone 2.7.  A solution of 2.70 (5.13 g, 13.7 mmol, 1.0 equiv) in MeOH (140 mL) was 
prepared in an oven-dried round-bottomed flask.  Cerium chloride (10.2 g, 41.4 mmol, 3.0 equiv) 
was added and dissolved over 10 min.  The homogeneous solution was cooled to 0 °C and 
sodium borohydride (3.1 g, 82.2 mmol, 6.0 equiv) was added in three portions over 15 min.  The 
reaction was warmed to ambient temperature (23 °C), diluted with Et2O (150 mL), and treated 
with 1N HCl (150 mL).  The organic layer was separated and the aqueous layer was further 
extracted with Et2O (2 x 150 mL).  The organic layers were combined, washed with 1N HCl 
(100 mL) followed by brine (200 mL), dried with Na2SO4, and concentrated in vacuo.  
Purification by flash chromatography (SiO2 0 → 40% EtOAc/hexanes) provided 3.23 g (68%) 
cyclohexenone 2.7 as a yellow oil.  TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.6 ; 
1
H NMR (500 
MHz, CDCl3): δ 7.39-7.31 (m, 5H), 6.71 (s, 1H), 4.56, 4.54 (ABq, J=12 Hz, 2H), 3.45 (app m, 
J=6.5, 1.5 Hz, 2H), 2.74 (s, 1H), 2.53 (dt, J = 16.5, 4.5 Hz, 1H), 2.48 (m, 2H), 2.40-2.33 (m, 3H), 
2.12-2.07 (m, 1H), 1.78-1.71 (m, 1H), 1.42 (s, 9H); 
13
C NMR (125 MHz; CDCl3): δ 198.8, 
172.1, 146.8, 138.2, 137.8, 128.2 (2), 127.5, 127.4, 126.7, 79.9, 73.0, 72.5, 37.0, 36.8, 34.1, 27.9 
(3), 25.8, 25.3; IR (thin film): 3091, 3064, 3031, 2978, 1723, 1675, 1359, 1146 cm
-1
; HRMS 
(+ESI) m/z calcd for C21H28LiO4 [M + Li]
+
: 351.2148, found: 351.2144. 
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Tri-substituted cyclohexanone 2.6.  Copper(I) bromide-dimethyl sulfide complex (0.6 g, 2.9 
mmol, 15 mol %) was weighed into an oven-dried round-bottomed flask and suspended in THF 
(200 mL).  HMPA (6.78 mL, 38.9 mmol, 2.0 equiv) was added and the solution became 
homogeneous over 10 min.  Following cooling to -78 °C, 2-methyl-1-propenylmagnesium 
bromide (0.5 M in THF, 117 mL, 3.0 equiv) was added with vigorous stirring.  A separate 
solution of 2.7 (6.7 g, 19.5 mmol, 1.0 equiv) in THF (10 mL) was prepared with TMSCl (6.2 
mL, 48.7 mmol, 2.5 equiv) and was added to the cuprate solution via syringe pump over 1 h.  
The reaction was warmed to ambient temperature (23 °C) and stirred for 12 h.  After this time, 
full conversion of 2.7 to the silyl enol ether had taken place, as indicated by TLC, and the 
reaction was subsequently diluted with Et2O (150 mL) and quenched with saturated NH4Cl (150 
mL).  Stirring was continued until the aqueous layer turned bright blue.  1N HCl (150 mL) was 
added and the biphasic solution was stirred vigorously until TLC indicated full conversion of the 
silyl enol ether to the ketone.  The organic layer was separated and the aqueous layer was further 
extracted with Et2O (2 x 150 mL).  The organic layers were combined, washed with brine (300 
mL), dried with Na2SO4, and concentrated in vacuo.  Purification by flash chromatography (SiO2 
0 → 30% EtOAc/hexanes) gave 5.67 g (73%) of the tri-substituted cyclohexanone 2.6 as a 
yellow oil.  TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.8 ; 
1
H NMR (500 MHz, CDCl3): δ  7.37-7.30 
(m, 5H), 4.91 (dd, J = 10, 1 Hz, 1H), 4.46, 4.44 (ABq, J=12, 2H), 3.50 (dd, J = 9.0, 3.0 Hz, 1H), 
3.26 (dd, J = 8.5, 7.0 Hz, 1H), 2.42 (dt, J = 7.0, 4.0 Hz, 2H), 2.38-2.28 (m, 4H), 2.21 (dt, J = 9.0, 
2.0 Hz, 1H), 2.14 (dt, J = 13.0, 3.0 Hz, 1H), 1.89-1.82 (m, 1H), 1.76 (s, 3H), 1.71-1.64 (m, 2H), 
1.57 (s, 3H), 1.45 (s, 9H) ; 
13
C NMR (125 MHz; CDCl3): δ 211.5, 172.9, 138.3, 134.0, 128.1 (2), 
127.4, 127.3 (2), 126.5, 79.6, 72.9, 72.3, 53.3, 45.7, 42.4, 41.4, 33.4, 30.3, 27.9 (3), 25.6, 21.9, 
18.4 ;  IR (thin film): 3339, 3031, 2978, 1732, 1711, 1448, 1362 cm
-1
; HRMS (+ESI) m/z calcd 
for C25H37O4 [M + H]
+
: 401.2692, found: 401.2683. 
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Allyl chloride 2.76.  N-chlorosuccinimide (15.4 g, 115 mmol, 1.1 equiv) was weighed into an 
oven-dried round-bottomed flask and suspended in CH2Cl2 (200 mL).  The slurry was cooled to 
0 °C and Me2S (10.0 mL, 133 mmol, 1.28 equiv) was added dropwise over 5 min giving a white 
solution.  3,5,5-Trimethyl-2-cyclohexen-1-ol (16.0 mL, 105 mmol, 1.0 equiv) was added 
dropwise with vigorous stirring to provide a clear solution.  Within 5 min, precipitate formed.  
The reaction proceeded at 0 °C for 2 h, was concentrated in vacuo, taken up in pentane (250 
mL), immediately forming a white precipitate, and placed in the freezer for 4 h.  Once the 
precipitation was complete, the mixture was washed with brine (2 x 150 mL), dried with 
Na2SO4, and concentrated in vacuo.  Allyl chloride 2.76 was isolated as a yellow oil (14.36 g, 
79%) that was taken on without purification.  TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.8 ; 
1
H NMR 
(500 MHz, CDCl3): δ 5.51-5.5 (m, 1H), 4.66-4.63 (m, 1H), 2.0-1.94 (m, 2H), 1.72 (s, 3H), 1.69-
1.66 (m, 2H), 1.04 (s, 3H), 0.91 (s, 3H); 
13
C NMR (125 MHz; CDCl3): δ 137.3, 122.0, 56.7, 
45.7, 43.5, 31.7, 30.7, 25.8, 23.6;  IR (thin film): 3044, 2951, 2898, 1667, 1460, 1436, 817, 726 
cm
-1
.  The parent molecular ion (M+) was unable to be detected by various methods. 
 
Homoallylic alcohol 2.74.  To an oven-dried round-bottomed flask, zinc (9.0 g, 136 mmol, 3.6 
equiv) and LiCl (1.16 g, 27.3 mmol, 0.7 equiv) were added.  The flask and its contents were then 
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flame-dried under vacuum.  After cooling for 3 min, THF (13.7 mL) was slowly added with 
vigorous stirring.  Fast addition of 1,2-dibromoethane (0.71 mL, 6.8 mmol, 0.18 equiv) lead to 
exothermic activation of the zinc, observed by rapid evolution of ethene gas. Note: if this process 
does not occur on its own accord, a heat gun may be employed to initiate the activation.  Excess 
pressure was eliminated by vacuum.  The solution was cooled slightly at 23 °C over 5 min 
before being further cooled to 0 °C.  A solution of the 2.6 (0.2 g, 0.5 mmol, 0.013 equiv) in THF 
(2.4 mL) was added dropwise by syringe followed by slow addition of 2.76 (6 g, 37.9 mmol, 1 
equiv) in THF (9.6 mL) via syringe pump at a rate of 4.5 mL/h.  The reaction proceeded for an 
additional 18 h at 0 °C before being quenched with saturated NH4Cl solution (100 mL).  The 
organic phase was separated and the aqueous phase was further extracted with EtOAc (3 x 100 
mL).  The organic layers were combined, washed with brine (200 mL), dried with Na2SO4, and 
concentrated in vacuo.  Purification by flash column chromatography (SiO2 0 → 50% 
EtOAc/hexanes) yielded 93 mg (35%) of the desired homoallylic alcohol 2.74 as a pale yellow 
oil.  TLC (EtOAc:hexanes, 2:8 v/v): Rf  = 0.6 ; 
1
H NMR (500 MHz, CDCl3): δ 7.36-7.31 (m, 
5H), 5.93 (dd, J=10.5, 2.5 Hz, 1H), 5.57 (ddd, J=10.5, 6.5, 2 Hz, 1H), 4.74 (ddd, J=10.5, 1, 1 Hz, 
1H), 4.46, 4.43 (ABq, J=12 Hz, 2H), 3.43 (dd, J=9, 3.5 Hz, 1H), 3.17 (dd, J=9, 7.5 Hz, 1H), 2.36 
(m, 1H), 2.26 (q, J=10.5 Hz, 1H), 2.01 (m, 1H), 1.83 (m, 6H), 1.71 (s, 3H), 1.62 (s, 3H), 1.45 (m, 
3H), 1.42 (s, 9H), 1.28 (m, 4H), 1.15 (s, 3H), 0.99 (s, 6H) ; 
13
C NMR (125 MHz; CDCl3): δ 
173.4, 138.8, 133.9, 132.3, 128.2 (2), 128.1, 127.5 (2), 127.3, 123.0, 79.4, 79.3, 73.8, 73.0, 45.0, 
44.3, 42.6. 41.1, 39.8, 38.1, 33.9, 33.8, 32.5, 30.5, 28.5, 28.2 (3), 25.8, 25.3, 24.6, 24.3, 18.7; IR 
(thin film): 3517, 3028, 2928, 1729, 1454, 1365 cm
-1
; HRMS (+ESI) m/z calcd for C34H53O4 [M 
+ H]
+
: 525.3944, found: 525.3949. 
104 
 
 
Isovaleric ester 2.77.  To a solution of 2.74 (0.149 g, 0.284 mmol, 1.0 equiv) in EtOH (16 mL) 
was added Pd(OH)2 on carbon (0.16 g, 20 wt%, 0.228 mmol, ).  A H2 balloon was placed atop 
the flask and the flask was evacuated three times under high vacuum.  The reaction proceeded 
for 18 h at which point an aliquot was removed to check the reaction with 
1
H NMR to insure the 
cyclohexene had been reduced.  The reaction mixture was filtered through a pad of Celite 
(washed with EtOAc), concentrated in vacuo, and taken on directly to the next step.     
 The crude primary alcohol was dissolved in CH2Cl2 (10 mL) and Et3N (0.24 mL, 1.94 
mmol, 6.8 equiv) and cooled to 0 °C.  Isovaleryl chloride (0.15 mL, 1.39 mmol, 4.3 equiv) was 
added dropwise and the reaction proceeded for 5 h at which point TLC showed completion of the 
reaction.  The crude reaction mixture was concentrated directly in vacuo and purified by column 
chromatography (SiO2 0 → 30% EtOAc/hexanes) to give 0.127 g (86%) of 2.77.  TLC 
(EtOAc:hexanes, 3:7 v/v): Rf  = 0.75 ; 
1
H NMR (500 MHz, CDCl3): δ 4.72 (d, J = 10.5 Hz, 1H), 
4.03 (dd, J = 10.5, 2.0 Hz, 1H), 3.74 (dd, J = 10.0, 7.5 Hz, 1H), 2.44-2.39 (m, 1H), 2.30-2.27 (m, 
1H), 2.15 (dd, J = 6.5, 1.5 Hz, 2H), 2.11-2.04 (m, 3H), 1.91 (dt, J = 14.0, 3.5 Hz, 2H), 1.70 (s, 
3H), 1.62 (s, 3H), 1.54-1.48 (m, 4H), 1.40 (s, 9H), 1.27-1.19 (m, 10H), 1.03 (s, 3H), 0.99 (s, 3H), 
0.94 (d, J = 1.5, 3H), 0.93 (d, J = 1.5, 3H), 0.89 (s, 3H); 
13
C NMR (125 MHz; CDCl3): δ 173.4, 
173.1, 132.9, 127.4, 79.3, 78.6, 75.1, 67.4, 45.0, 44.3, 43.4, 42.6, 41.2, 40.7, 38.4, 36.0, 33.2, 
32.2, 32.1, 30.9, 28.0 (3), 27.4, 26.1, 25.7, 25.5, 24.4, 22.4, 20.9, 19.3, 18.6;  IR (thin film): 
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3532, 2960, 2922, 2869, 1729, 1708, 1463 cm
-1
; HRMS (+ESI) m/z calcd for C32H56LiO5 [M + 
Li]
+
: 527.4288, found: 527.4310. 
 
Carboxylic acid A1.  A solution of isovaleric ester 2.77 (0.085 g, 0.16 mmol, 1.0 equiv) in 
CH2Cl2 (4.0 mL) was cooled to 0 °C.  Titanium tetrachloride (1.0 M in CH2Cl2, 0.41 mL, 2.5 
equiv) was added dropwise via syringe.  After 10 min, TLC indicated reaction completion and 
quenching was done at 0 °C with saturated NaHCO3 (15 mL).  After stirring for 2 min, 1N HCl 
(10 mL) was added.  The organic phase was separated and the aqueous layer was further 
extracted with CH2Cl2 (3 x 10 mL).  The organic layers were combined, washed with brine (15 
mL), dried with Na2SO4, and concentrated in vacuo to give 73.5 mg of carboxylic acid A1 
(99%.).  The compound was of sufficient purity to be taken on to the next step without further 
purification.  TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.7 ; 
1
H NMR (500 MHz, CDCl3): δ 4.74-4.72 
(d, 10 Hz, 1H), 4.05 (dd, J = 11.0, 6.5, 1H), 3.75 (dd, J = 11.0, 7.5 Hz, 1H), 2.62 (ddd, J=16, 
12.5, 8.5 Hz,  1H), 2.34-2.22 (m, 2H),  2.17 (app d, J = 6.5 Hz, 2H), 2.11-2.06 (m, 1H), 2.02-
1.95 (m, 1H), 1.71 (s, 3H), 1.62 (s, 3H), 1.56-1.50 (m, 3H), 1.46-1.29 (m, 12H), 1.24-1.16 (m, 
2H), 1.04 (s, 3H), 0.99 (s, 3H), 0.95 (d, J = 0.8, 3H), 0.94 (d, J = 0.8, 3H), 0.88 (s, 3H), O-H 
proton not observed; 
13
C NMR (125 MHz; CDCl3): δ 180.1, 173.3, 133.3, 127.2, 78.8, 67.4, 
44.9, 44.3, 43.5, 42.6, 41.3, 40.4, 38.5, 36.0, 32.3, 32.2, 31.4, 31.0, 27.5, 25.8, 25.7, 25.6, 24.5, 
22.4 (2), 21.0, 19.4, 18.6;  IR (thin film): 3339, 3031, 2978, 1732, 1711, 1448, 1362 cm
-1
; 
HRMS (-ESI) m/z calcd for C28H47O5 [M - H]
-
: 463.3424, found: 463.3429. 
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Aldehyde acid 2.73.  A solution of carboxylic acid A1 (0.151 g, 0.325 mmol, 1.0 equiv) was 
dissolved in a mixed solvent system of MeOH/CH2Cl2 (1:5, 6 mL: 30 mL) and cooled to -78 °C.  
Ozone was bubbled through the reaction solution until a blue color persisted.  Excess ozone was 
removed by blowing N2 gas over the solution with stirring for 10 min.  DMS (0.24 mL, 32.5 
mmol, 10.0 equiv) was added and the reaction was slowly warmed to ambient temperature (23 
°C) over 3 h at which time TLC indicated the reaction was complete.  Purification by flash 
chromatography (SiO2 0 → 60% EtOAc/hexanes) gave 0.116 g (81%) of aldehyde acid 2.73 as a 
colorless oil.  TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.3; 
1
H NMR (500 MHz, CDCl3): 9.57 (dd, 
J=4, 1 Hz, 1H), 3.96-3.88 (qd, J=11.5, 6.5  Hz, 2H), 2.74 (ddd, J=16.0, 12.5, 3.5 Hz, 1 H), 2.51 
(m, 2H), 2.44 (app d, J=5 Hz, 2H), 2.11-2.04 (m, 3H), 1.72-1.54 (m, 8H), 1.48-1.25 (m, 8H), 1.1 
(s, 3H), 1.0 (s, 3H), 0.96 (s, 3H), 0.95 (s, 3H), 0.9 (s, 3H), O-H proton not observed ; 
13
C NMR 
(125 MHz; CDCl3): δ 204.0, 179.1, 172.8, 78.3, 66.8, 54.1, 44.0, 43.2, 42.6, 39.3, 38.4, 36.2, 
35.9, 32.3, 31.8, 30.9, 29.6, 27.4, 26.0, 25.5, 23.0, 22.4, 22.3, 20.7, 19.2 ;  IR (thin film): 3529, 
2951, 2928, 2869, 1726, 1709 cm
-1
; HRMS (-ESI) m/z calcd for C25H41O6 [M - H]
-
: 437.2909, 
found: 437.2926. 
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Representative procedure for Nucleophile Catalyzed Aldol-Lactonization process as 
described for β-lactone 13.   
Racemic: 
Entry 1.  To an oven-dried round-bottomed flask, modified Mukaiyama’s reagent (7.5 mg, 213 
µmol, 3.0 equiv) was added and azeotroiped with xylenes in vacuo.  It was then dissolved in in 
CH2Cl2 (1.5 mL) and Et3N (50.0 µL, 355 µmol, 5.0 equiv).  A separate solution of 2.73 (31.1 
mg, 71 µmol, 1.0 equiv) was prepared in CH2Cl2 (0.5 mL) and was subsequently added via 
syringe pump over 1 h.  Purification (SiO2 0 → 30% EtOAc/hexanes) provided a mixture of 
diastereomers (3:1); 2.78 (30%, 9.1 mg) and 2.78’ (9.4%, 2.8 mg).      
Entry 2.  Prepared according to representative procedure (Entry 1) utilizing TsCl (3.5 mg, 18 
µmol, 1.5 equiv) and (±)-HBTM (3.3 mg, 12.3 µmol, 1.0 equiv) in CH2Cl2 (0.27 mL), (i-Pr)2NEt 
(10 µL, 6.16 µmol, 5.0 equiv), 2.73 (5.4 mg, 12.3 µmol, 1.0 equiv) in CH2Cl2 (0.5 mL).  Both 
TsCl and (±)-HBTM were azeotroped with xylenes in vacuo.  Purification (SiO2 0 → 30% 
EtOAc/hexanes) provided a mixture of diastereomers (1:1); 2.78 (10%, 500 µg) and 2.78’ (10%, 
500 µg).      
 
Asymmetric: 
Entry 3.  To an oven-dried round-bottomed flask, modified Mukaiyama’s reagent (43 mg, 123 
µmol, 3.0 equiv) was added followed by (S)-HBTM (11 mg, 41 µmol, 1.0 equiv).  The two 
solids were azeotroped with xylenes in vacuo.  The mixture was dissolved in CH2Cl2 (1.0 mL) 
and (i-Pr)2NEt (34 µL, 205 µmol, 5.0 equiv) with stirring.  A separate solution of 2.73 (18 mg, 
4.1 µmol, 1.0 equiv) was prepared in CH2Cl2 (2 mL) and was subsequently added via syringe 
pump over 1 h.  The reaction then proceeded for an additional 18 h, was concentrated in vacuo, 
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and purified (SiO2 0 → 30% EtOAc/hexanes) to provide a mixture of diastereomers (1:1): (-)-
2.78 (2.7 mg,16%)  and (-)2.78’ (2.8 mg, 16%).  TLC (EtOAc:hexanes, 3:7 v/v). 
β-lactone (-)-13. Rf  = 0.8; [α]D
20
 = -36.00 (c = 0.11, CHCl3); 
1
H NMR (500 MHz, CDCl3): 4.76 
(dd, J=6.0, 4.5 Hz, 1H), 4.15 (dd, J=11.5, 6.5, 1H), 4.04 (dd, J=11.0, 6.0, 1H), 3.92 (dt, J= 10, 6 
Hz, 1H), 2.22 (dd, J=7.5, 2 Hz, 2H), 2.15-2.09 (m, 3H), 2.03-1.99 (m, 3H), 1.76-1.71 (m, 3H), 
1.41-1.37 (m, 7H), 1.28-1.27 (m, 3H), 1.03 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H), 0.97 (s, 3H), 0.92 
(s, 3H) ; 
13
C NMR (125 MHz; CDCl3): δ 173.1, 172.2, 78.8, 77.0, 67.5, 54.4, 53.6, 48.6, 44.2, 
43.3, 41.7, 39.5, 38.6, 36.1, 31.3, 30.8, 29.7, 27.5, 26.9, 25.6, 25.2, 22.4, 21.1, 19.0 (2); IR (thin 
film): 2957, 2860, 1824, 1735, 1637, 1297 cm
-1
; HRMS (+ESI) m/z calcd for C25H40LiO5 [M + 
Li]
+
: 427.3036, found: 427.3031. 
β-lactone (-)-2.78’. Rf  = 0.6; 
1
H NMR (500 MHz, CDCl3): 4.76 (dd, J=6.0, 4.5 Hz, 1H), 4.15 
(dd, J=11.5, 6.5 Hz, 1H), 4.04 (dd, J=11.0, 6.0 Hz, 1H), 3.92 (dt, J= 10, 6 Hz, 1H), 2.22 (dd, 
J=7.5, 2 Hz, 2H), 2.15-2.09 (m, 3H), 2.03-1.99 (m, 3H), 1.76-1.71 (m, 3H), 1.41-1.37 (m, 7H), 
1.28-1.27 (m, 3H), 1.03 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H), 0.97 (s, 3H), 0.92 (s, 3H) ; 
13
C NMR 
(125 MHz; CDCl3): δ 173.1, 172.2, 78.8, 77.0, 67.5, 54.4, 53.6, 48.6, 44.2, 43.3, 41.7, 39.5, 38.6, 
36.1, 31.3, 30.8, 29.7, 27.5, 26.9, 25.6, 25.2, 22.4, 21.1, 19.0 (2); IR (thin film): 2957, 2860, 
1824, 1735, 1637, 1297 cm
-1
; HRMS (+ESI) m/z calcd for C25H40LiO5 [M + Li]
+
: 427.3036, 
found: 427.3031. 
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Table A1. Analysis of coupling constants for β-lactones 2.78 and 2.78’. 
 
Cmpd. 
J14, 15 (Hz) J15, 6  (Hz) J6, 7α (Hz) J6, 7β (Hz) J7α, 8 (Hz) J7β, 8 (Hz) J 8, 14 (Hz) J 13, 14 (Hz) 
2.78 4.5 6.0 6.0 11.0 nd nd nd nd 
2.78’ 4.0 4.0 4.0 8.0 5.5 nd 11.5 nd 
*Note:  Indistinguishable couplings, due to aliphatic overlap are indicated by ‘nd’ in table. 
 
Epimerized aldehyde-acid (±)-2.73’.  TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.28; 
1
H NMR (500 
MHz, CDCl3): 9.58 (d, J=2.5 Hz, 1H), 4.01 (dd, J=11, 5.5 Hz, 1H), 3.94 (dd, J=11, 5.5 Hz, 1H), 
2.81-2.75 (m, 1H), 2.65-2.61 (m, 2H), 2.55-2.48 (m, 1H), 2.18 (app d, 2H), 2.14-2.01 (m, 5H), 
1.74-1.64 (m, 6H), 1.44-1.34 (m, 6H), 1.09 (s, 3H), 1.01 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H), 0.91 
(s, 3H); 
13
C NMR (125 MHz; CDCl3): δ 204.1, 179.1, 172.8, 78.3, 66.8, 54.1, 44.0, 43.2, 42.7, 
39.3, 38.4, 36.2, 35.9, 32.3, 31.8, 30.9, 29.6, 27.4, 26.0, 25.5, 23.0, 22.4 (2), 20.7, 19.2. 
 
Entry 4.  Prepared according to representative procedure (Entry 3) utilizing modified 
Mukaiyama’s reagent (24 mg, 68 µmol, 3.0 equiv) and (R)-HBTM (6.1 mg, 23 µmol, 1.0 equiv) 
in CH2Cl2 (0.5 mL), (i-Pr)2NEt (19 µL, 114 µmol, 5.0 equiv), 2.73 (10 mg, 2.3 µmol, 1.0 equiv) 
in CH2Cl2 (2 mL).  Purification (SiO2 0 → 30% EtOAc/hexanes) provided a mixture of 
diastereomers (1:2):  (+)-2.78 (6.3%, 600 µg) and (+)-2.78’ (12.5%, 1.2 mg). 
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Entry 5.  Prepared according to representative procedure (Entry 3) utilizing modified 
Mukaiyama’s reagent (15 mg, 42 µmol, 3.0 equiv) and (-)-BTM (3.5 mg, 13.9 µmol, 1.0 equiv) 
in CH2Cl2 (0.3 mL), (i-Pr)2NEt (11 µL, 69 µmol, 5.0 equiv), 2.73 (6.1 mg, 13.9 µmol, 1.0 equiv) 
in CH2Cl2 (1.0 mL). Purification (SiO2 0 → 30% EtOAc/hexanes) provided a mixture of 
diastereomers (1.2:1): (+)-2.78 (11.4%, 600 µg) and (+)-2.78’ (9.5%, 500 µg).     
 
Entry 6.  Prepared according to representative procedure (Entry 3) utilizing modified 
Mukaiyama’s reagent (12 mg, 34 µmol, 3.0 equiv) and TMSQD (4.5 mg, 11.4 µmol, 1.0 equiv) 
in CH2Cl2 (0.25 mL), (i-Pr)2NEt (10 µL, 57 µmol, 5.0 equiv), 2.73 (5.0 mg, 11.4 µmol, 1.0 
equiv) in CH2Cl2 (1.0 mL).  Purification (SiO2 0 → 30% EtOAc/hexanes) provided a mixture of 
diastereomers (1.3:1): (-)-2.78 (19%, 900 µg) and (-)-2.78’ (13.9%, 666 µg) and (± 2.73’) (27%, 
1.35 mg).   
 
Entry 7.  Prepared according to representative procedure (Entry 3) utilizing modified 
Mukaiyama’s reagent (24 mg, 68 µmol, 3.0 equiv) and TMSQN (9.0 mg, 23.0 µmol, 1.0 equiv) 
in CH2Cl2 (0.5 mL), (i-Pr)2NEt (18.7 µL, 114 µmol, 5.0 equiv), 2.73 (10.0 mg, 23.0 µmol, 1.0 
equiv) in CH2Cl2 (2.0 mL).  Purification (SiO2 0 → 30% EtOAc/hexanes) provided a mixture of 
diastereomers (2:1): (+)-2.78 (10 %, 900 µg), [α]D
20
 = +10.77 (c = 0.09, CHCl3), (+)-2.78’ (4%, 
39 µg) and (±)-2.73’ (34%, 3.4 mg).  
 
Entry 8.  Prepared according to representative procedure (Entry 3) utilizing modified 
Mukaiyama’s reagent (12 mg, 34 µmol, 3.0 equiv) and TMSQN (4.5 mg, 11.4 µmol, 1.0 equiv) 
in CH2Cl2 (0.25 mL), (i-Pr)2NEt (3.7 µL, 23 µmol, 2.0 equiv), 2.73 (5.0 mg, 11.4 µmol, 1.0 
equiv) in CH2Cl2 (1.0 mL).  Purification (SiO2 0 → 30% EtOAc/hexanes) provided a mixture of 
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diastereomers (5:1): (+)-2.78 (12.5%, 600 µg) and (-)-2.78’ (2.7%, 130 µg) and (±)-2.73’ (18%, 
900 µg).     
 
Entry 9.  Prepared according to representative procedure (Entry 3) utilizing modified 
Mukaiyama’s reagent (24 mg, 68 µmol, 3.0 equiv) and TMSQN (2.4 mg, 6.2 µmol, 0.27 equiv) 
in CH2Cl2 (0.5 mL), (i-Pr)2NEt (18.7 µL, 114 µmol, 5.0 equiv), 2.73 (10.0 mg, 23.0 µmol, 1.0 
equiv) in CH2Cl2 (2.0 mL).  Purification  (SiO2 0 → 30% EtOAc/hexanes) provided a mixture of 
diastereomers (2:1): (+)-2.78 (12% on 5 mg scale, 600 µg and 6.2% on 10 mg scale, 600 µg) and 
(+)-2.78’ (3%, 300 µg). and (±)-2.73 (25%, 2.5 mg). 
 
p-Bromobenzyl amide.   
 
From entry 3: (-)-A2.  To a vial containing p-bromobenzylamine (0.9 mg, 4.8 µmol, 1.8 equiv), a 
separately prepared solution of (-)-2.78 (1.1 mg, 2.6 µmol, 1.0 equiv) in THF (0.2 mL) was 
added.  The reaction proceeded for 72 hours after which it was loaded directly onto one 10 cm x 
20 cm TLC plate and eluted three times in 30:70 EtOAc/hexanes, v/v, Rf = 0.2.  The silica was 
washed with CH2Cl2 and provided (-)-A2 (600 µg, 31%) upon concentration; (Note:  A sufficient 
amount of (-)-S2 was isolated to obtain 
1
H NMR but was insufficient for 
13
C NMR) 
1
H NMR 
(500 MHz, CDCl3): 7.48 (d, J = 8.5 Hz, 2H), 7.21 (d, J = 8.5 Hz, 2H), 6.09 (app t, J = 5 Hz, 1H), 
4.50 (dd, J = 15, 6 Hz, 1H), 4.42-4.36 (m, 2H), 4.17-4.12 (m, 2H), 4.00 (app t, J = 9 Hz, 1H), 
2.82 (q, J = 8.0 Hz, 2H), 2.22 (app d, J = 7.5 Hz, 2H), 2.16-2.06 (m, 4H), 2.02-1.96 (m, 2H), 
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1.83-1.71 (m, 6H), 1.38-1.36 (m, 3H), 1.30-1.27 (m, 3H), 1.02 (s, 3H), 1.00 (s, 3H), 0.99 (s, 3H), 
0.97 (s, 3H), 0.91 (s, 3H); IR (thin film): 3100, 2925, 1726, 1643, 1457, 1256, 1157, 1066 cm
-1
; 
HRMS (ESI+) m/z calcd. For C32H49BrNO5 [M+H]
+
: 606.2794; found 606.2773.  Enantiomeric 
excess was determined by HPLC analysis in comparison with authentic racemic material using a 
Chiralcel IA column: hexanes:iPrOH = 75:25, flow rate 1.0 mL/min, λ = 210 nm: tmajor = 8.56 
min, tminor = 10.2 min; 78% ee. 
 
 From Entry 3: (-)-A3.  To a vial containing p-bromobenzylamine (1.7 mg, 9.1 µmol, 2.75 
equiv), a separately prepared solution of (-)-2.78’ (1.2 mg, 2.8 µmol, 1.0 equiv) in THF (0.2 mL) 
was added.  The reaction proceeded for 72 hours after which it was loaded directly onto one 10 
cm x 20 cm TLC plate and eluted three times in 30:70 EtOAc/hexanes, v/v, Rf = 0.2.  The silica 
was washed with CH2Cl2 and provided (-)-A3 (1.3 mg, 75%) upon concentration; (Note:  A 
sufficient amount of (-)-A3 was isolated to obtain 
1
H NMR but was insufficient for 
13
C NMR) 
1
H 
NMR (500 MHz, CDCl3): 7.49 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 6.28-6.26 (m, 1H), 
4.53 (dd, J = 15.5, 6.5 Hz, 1H), 4.42-4.37 (m, 3H), 4.17 (dd, J = 10.5, 4.0 Hz, 1H), 4.02 (dd, J = 
11.0, 6.5 Hz, 1H), 2.67-2.63 (m, 1H), 2.36-2.29 (m, 1H), 2.21 (app d, J = 6.5 Hz, 2H), 2.15-2.01 
(m, 4H), 1.88-1.81 (m, 1H), 1.76-1.71 (m, 3H), 1.42-1.35 (m, 5H), 1.25-1.17 (m, 5H), 1.07 (s, 
3H), 1.02 (s, 3H), 0.98 (s, 3H), 0.96 (s, 3H), 0.91 (s, 3H); IR (thin film): 3100, 2925, 1726, 1643, 
1457, 1256, 1157, 1066 cm
-1
; HRMS (ESI+) m/z calcd. For C32H49BrNO5 [M+H]
+
: 606.2794; 
found 606.2773.  (-)-A3: Enantiomeric excess was determined by HPLC analysis in comparison 
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with authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 90:10, flow rate 
0.9 mL/min, λ = 230 nm: tmajor = 14.218 min, tminor = 35.013 min; 20% ee.   
 
For remaining entries, the procedure followed protocols for Entry 1.  Yields for A2 and A3 were 
not determined, and, upon preparatory TLC, the samples were immediately subjected to HPLC 
analysis for ee determination.   
 
Entry 4. (+)-A2: Enantiomeric excess was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 75:25, flow rate 1.0 
mL/min, λ = 210 nm: tmajor = 8.62 min, tminor = 10.3 min; 84% ee; (+)-A2: Chiralcel IA column: 
hexanes:iPrOH = 90:10, flow rate 0.9 mL/min, λ = 230 nm: tmajor = 14.218 min, tminor = 35.013 
min; 20% ee.       
 
Entry 5.  (+)-A2: Enantiomeric excess was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 75:25, flow rate 1.0 
mL/min, λ = 210 nm: tmajor = 8.57 min, tminor = 10.32 min; 81% ee; (+)-A2:  Chiralcel IA column: 
hexanes:iPrOH = 90:10, flow rate 0.9 mL/min, λ = 230 nm: tmajor = 14.218 min, tminor = 35.013 
min; 60% ee.   
 
Entry 6.  (-)-A2: Enantiomeric excess was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 75:25, flow rate 1.0 
mL/min, λ = 210 nm: tmajor = 8.37 min, tminor = 10.21 min; 93% ee; (-)-A2: Chiralcel IA column: 
hexanes:iPrOH = 90:10, flow rate 0.9 mL/min, λ = 230 nm: tmajor = 14.218 min, tminor = 35.013 
min; 77% ee.      
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Entry 7.  (+)-A2: Enantiomeric excess was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 75:25, flow rate 1.0 
mL/min, λ = 210 nm: tmajor = 8.57 min, tminor = 10.32 min; 90% ee. 
 
Entry 8.  (+)-A2: Enantiomeric excess was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 75:25, flow rate 1.0 
mL/min, λ = 210 nm: tmajor = 8.57 min, tminor = 10.32 min; 92% ee. 
 
Entry 9.  (+)-A2: Enantiomeric excess was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 75:25, flow rate 1.0 
mL/min, λ = 210 nm: tmajor = 8.57 min, tminor = 10.32 min; 90% ee. 
 
(+)-Spongiolactone, 2.1 and Regioisomeric (+)-Spongiolactone 2.79.  β-lactone (+)-2.78 (2.7 
mg, 6.4 µmol, 1.0 equiv) was dissolved in CH2Cl2 and cooled to 0 °C.  SOCl2 (1.99 µL, 27.3 
µmol, 4.25 equiv) was added dropwise over 2 min.  The reaction was warmed to ambient 
temperature (23 °C) and stirred until TLC indicated its completion.  The reaction was 
concentrated in vacuo and loaded directly onto a silica column for purification (SiO2 0 → 30% 
EtOAc/hexanes) providing 1.4 mg of 2.1 (54%) as well as 600 µg of regioisomeric olefin 2.79 
(23%).     
 
Spongiolactone (2.1): TLC (EtOAc:hexanes, 2:8 v/v): Rf  = 0.8; [α]D
20
 = +45.5 (c = 0.04, CHCl3); 
1
H NMR (500 MHz, CDCl3): 4.73 (dd, J = 3.7, 3.7 Hz, 1H), 4.14, 4.04 (dd J = 11.1, 6.2 Hz, 2H), 
115 
 
3.90 (dt, J = 11.2, 5.7 Hz, 1H), 3.05 (dd, J = 10.5, 5.5 Hz, 1H), 2.67 (d, J = 13.0 Hz, 1H), 2.43 
(d, J = 11.0 Hz, 1H), 2.29 (d, J = 17.0 Hz, 1H), 2.20 (app d, J = 7.1 Hz, 2H), 2.11-2.06 (m, 
2H),1.93 (m, 1H), 1.83 (m, 1H), 1.71-1.65 (m, 2H), 1.48-1.44 (m, 1H), 1.31-1.24 (m, 4H), 1.12-
1.11 (m, 2H), 0.97 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H), 0.85 (s, 3H), 0.78 (s, 3H); 
13
C NMR (125 
MHz; CDCl3): δ 172.9, 171.8, 139.4, 133.7, 79.9, 67.6, 54.3, 50.2, 49.9, 43.3, 39.7, 39.4, 38.3, 
36.8, 32.7, 31.4, 30.5, 30.3, 26.8, 26.5, 26.3, 25.6, 22.4 (2), 20.9 ;  IR (thin film): 2951, 2925, 
2866, 1829, 1725, 1626, 1462, 1294, 1107 cm
-1
; HRMS (+ESI) m/z calcd for C25H38LiO4 [M + 
Li]
+
: 409.2925, found: 409.2938. 
 
Regioisomeric spongiolactone (2.79): TLC (EtOAc:hexanes, 2:8 v/v): Rf  = 0.7 ; [α]D
20
 = +33.7 
(c = 0.03, CHCl3);  
1
H NMR (500 MHz, CDCl3): 5.58 (m, 1H), 4.84 (app t, J = 5.5 Hz, 1H), 4.15 
(dd, J = 5.5, 2.0 Hz, 2H), 4.07-4.02 (m, 1H), 2.55-2.50 (m, 1H), 2.49-2.43 (m, 1H), 2.34-2.30 
(m, 1H), 2.25 (app d, J = 6.5 Hz, 2H), 2.17-2.10 (m, 2H), 2.08-2.03 (m, 2H), 2.00-1.95 (m, 2H), 
1.89-1.84 (m, 2H), 1.82-1.78 (m, 1H), 1.21-1.18 (m, 4H), 1.04 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 
0.93 (s, 3H), 0.87 (s, 3H); 
13
C NMR (125 MHz; CDCl3): δ 173.1, 172.1,145.3, 120.0, 77.1, 67.1, 
55.3, 52.4, 49.2, 48.9, 43.3, 39.8, 39.5, 37.8, 36.0, 32.0, 31.4, 30.74, 30.72, 29.7, 25.6, 22.4 (2), 
19.9, 14.1;  IR (thin film): 2951, 2925, 2866, 1829, 1725, 1626, 1462, 1294, 1107 cm
-1
; HRMS 
(+ESI) m/z calcd for C25H38LiO4 [M + Li]
+
: 409.2925, found: 409.2938. 
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Table A2. Analysis of coupling constants for spongiolactone ((±)-2.1), regio-spongiolactone 
((±)-2.79), and regio, bis-epi spongiolactone ((±)-3.8).  
 
 
 
Cmpd J14, 15 
(Hz) 
J15, 6  
(Hz) 
J6, 7α 
(Hz) 
J6, 7β 
(Hz) 
J7α, 8 
(Hz) 
J7β, 8 
(Hz) 
J8, 14 
(Hz) 
J13, 14 
(Hz) 
(±)-3 3.5 6.0 6.0 11.0 NA NA NA 11.0 
(±)-16 6.0 6.0 4.0 10.5 5.0 1.5 11.5 nd 
(±)-17 3.5 3.5 7.5 4.0 5.5 nd 12.5 nd 
 
*Note:  Indistinguishable couplings, due to aliphatic overlap are indicated by ‘nd’ in table.   
NA denotes the lack of proton 8 in spongiolactone ((±)-2.1). 
 
Table A3. Comparison of 
1
H NMR data of natural
[1]
 and synthetic spongiolactone and 3’-
norspongiolactone
[2]
 in CDCl3.  
 
 
1.95-1.83 (m, 2H), 1.74-1.64 (m, 2H), 1.52-1.39 (m, 1H), 1.34-1.22 (m, 4H), 1.13-1.07 (m, 2H), 
0.95 (d, 6H), 0.94 (s, 3H), 0.85 (s, 3H), 0.78 (s, 3H); 
 
Pos. 
1
H NMR data-natural 
spongiolactone (500 
MHz) 
1
H NMR data-synthetic 
spongiolactone (500 
MHz) 
Δ ppm 
(natural-
synthetic)
 
1
H NMR data-3’-
norspongiolactone 
(400 MHz) 
1 1.90 1.95-1.83 (m, 2H) - 1.80 (m) 
2 1.47
i
, 1.10 
1.46, 1.11 (dt, J = 11.5, 
4.5 Hz) 
0.01, 0.01 1.45 (m), 1.08 (m) 
5 1.93, 1.02 1.93 (m), 1.02 0.0, 0.0 1.90 (m), 1.03 (m) 
i
J values were not reported in the original isolation paper
1
 for these resonances. 
                                                          
1
. L. Mayol, V. Piccialli, D. Sica, Tetrahedron Lett. 1987, 28, 3601-3604. 
2
. M. E. Rateb, W. E. Houssen, M. Schumacher, W. T. Harrison, M. Diederich, R. Ebel, M. Jaspars, J. Nat. 
Prod. 2009, 72, 1471-1476. 
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Table A3 Continued. 
 
Pos. 
1
H NMR data-natural 
spongiolactone (500 
MHz) 
1
H NMR data-synthetic 
spongiolactone (500 
MHz) 
Δ ppm 
(natural-
synthetic)
 
1
H NMR data-3’-
norspongiolactone 
(400 MHz) 
6 
3.90 (ddd, J = 11.0, 6.0, 
6.0 Hz) 
3.90 (overlapping ddd, J = 
11.0, 6.0, 6.0 Hz) 
0.0 
3.88 (ddd, J = 16.0, 
11.2, 6.0 Hz) 
7 3.04
a
, 2.66 
3.05 (dd, J = 13.5, 10.5 
Hz), 2.67 (app br d, J = 
12.5 Hz, 1H) 
0.01, 0.01 
3.02, (dd, J = 16.0, 
11.0 Hz), 2.68, (dd, 
J = 16.0, 6.0 Hz) 
11 2.29 
2.28 (app br d, J = 17.0 
Hz, 1H) 
0.01 2.28 (m) 
13 1.66 1.67 0.01 1.63 (m) 
14 2.42 
2.42 (app br d, J = 8.5 Hz, 
1H) 
0 2.39 (d, J = 11 Hz) 
15 
4.73 (dd, J = 6.0, 4.4 
Hz) 
4.73 (dd, J = 6.0, 3.5 Hz) 0.0 
4.71 (dd, J = 6.0, 
3.8 Hz) 
16 
4.14 (dd, J = 11.0, 6.6 
Hz), 4.04 (dd, J = 11.0, 
6.6 Hz) 
4.14 (dd, J = 11.0, 6.0 
Hz), 4.04 (dd, J = 11.0, 
6.0 Hz) 
0.0, 0.0 
4.12, 4.02 (dd, J = 
11.2, 6.5 Hz) 
17 0.77 0.78 (s) 0.01 0.76 (s) 
18 0.84 0.85 (s) 0.01 0.83 (s) 
19 0.96 0.97 (s) 0.01 0.95 (s) 
2’ 2.19i 2.21-2.19 (m) - - 
3’ 2.07i 2.11-2.05 (m) - - 
4’, 
5’ 
0.94 0.94 (d) 0.0 - 
 
Note:  Chemical shifts and corresponding J values are not for protons on carbons 3, 4, and 12 
due to overlap of aliphatic protons. 
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Table A4. Comparison of 
13
C NMR data of natural
[1] and synthetic spongiolactone and 3’-
norspongiolactone
[2] 
in CDCl3. 
 
 
Pos. 
13
C NMR data-
Natural 
(125 MHz) 
13
C NMR data-
Synthetic 
(125 MHz) 
Δ ppm 
(natural-
synthetic)
 
13
C NMR data-
norspongiolactone 
(100 MHz) 
1 38.3 38.3 0 38.3 
2 20.9 20.9 0 20.9 
3 39.7 39.6 0.1 39.6 
4 31.4 31.4 0 31.4 
5 49.9 49.8 0.1 49.9 
6 54.3 54.1 0.2 54.1 
7 30.5 30.6 0.1 30.4 
8 133.7 133.5 0.2 133.5 
9 139.4 138.9 0.5 139.0 
10  31.4  31.4 
11 26.3 26.0 0.3 26.2 
12 26.8 26.7 0.1 26.6 
13 36.8 36.6 0.2 36.6 
14 50.2 50.1 0.1 50.2 
15 79.9 80.0 0.1 80.1 
16 67.6 67.7 0.1 67.8 
17 26.5 26.2 0.3 26.0 
18 32.7 33.0 0.3 32.9 
19 30.3 30.4 0.1 30.4 
20 171.8 172.2 0.4 172.2 
1’ 172.9 173.2 0.3 173.7 
2’ 43.3 43.3 0 - 
3’ 25.6 25.6 0 - 
4’ 22.4 22.4 0 - 
5’ 22.4 22.4 0 - 
**Note:  Carbons 2’,3’,4’, 5’ excluded for norspongiolactone due to structural differences. 
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Chiral HPLC Analysis of (±)-A3:   
 
Chiralcel IA column: hexanes:iPrOH = 72:28, flow rate 1.0 mL/min, λ = 230 nm: t1= 8.422 min, 
t2= 9.542 min; racemic. 
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Chiral HPLC analysis of (+)-A3: 
 
Chiralcel IA column: hexanes:iPrOH = 72:28, flow rate 1.0 mL/min, λ = 230 nm: tmajor= 9.556 
min, tminor= 8.490 min; 90% ee. 
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Chiral HPLC analysis of A3: 
 
Chiralcel IA column: hexanes:iPrOH = 80:20, flow rate 1.0 mL/min, λ = 230 nm: t1= 6.21 min, 
t2= 9.82 min; racemic. 
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Chiral HPLC Analysis of (-)-A3:   
 
Chiralcel IA column: hexanes:iPrOH = 80: 20, flow rate 1.0 mL/min, λ = 230 nm: tmajor= 6.15 
min, tminor= 9.66 min; 64% ee. 
 
 
Regio, bis-epi spongiolactone (±)-3.8.  β-lactone (±)-3.13 (3.9 mg, 9.3 µmol, 1.0 equiv) was 
dissolved in CH2Cl2, Et3N (6.8 µL, 49.0 µmol, 5.25 equiv) was added and the mixture cooled to 
0 °C. Neat SOCl2 (3.0 µL, 39.4 µmol, 4.25 equiv) was added dropwise over 2 min with a 
123 
 
microliter syringe. The reaction was warmed to ambient temperature (23 °C) and stirred until 
TLC indicated complete consumption of starting material (~12 h). The reaction was concentrated 
in vacuo and loaded directly onto a silica column for purification (SiO2 0 → 30% 
EtOAc/hexanes) providing 0.2 mg of (±)-bis-epi spongiolactone (6%) and 1.8 mg of regio, bis-
epi spongiolactone ((±)-3.8, 48%). 
Regio, bis-epi spongiolactone (±)-3.8.  Rf = 0.61 (3:7-EtOAc/hexanes); IR (thin film) 3064, 
2954, 2925, 1821, 1807, 1637, 1267 cm
-1
; 
1
H-NMR (500 MHz, CDCl3) δ 5.49 (overlapping ddd, 
J = 5.0, 5.0, 2.5 Hz, 1H), 4.84 (app t, J = 3.5 Hz, 1H), 4.19 (dd, J = 11.0, 5.0 Hz, 1H), 3.96 (dd, J 
= 11.5, 6.0 Hz, 1H), 3.90 (d, J = 7.5, 4.0 Hz, 1H), 2.59-2.54 (m, 1H), 2.49 (dd, J = 12.5, 5.5 Hz, 
1H), 2.29-2.23 (m, 1H), 2.16 (dd, J = 8.0, 1.5 Hz, 2H), 2.12-2.01 (m, 2H), 1.96-1.89 (m, 1H), 
1.80-1.75 (m, 1H), 1.63 (overlapping ddd, J = 12.5, 12.5, 7.5 Hz, 1H), 1.58-1.45 (m, 3H), 1.42 
(overlapping ddd, J = 14.0, 14.0, 3.0 Hz, 1H), 1.2-1.1 (m, 4H), 0.99 (s, 3H), 0.90 (d, 6H), 0.84 
(s, 3H), 0.77 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 173.2, 171.2, 142.3, 126.8, 75.7, 67.4, 53.6, 
50.0, 47.6, 43.4, 39.6, 39.4, 38.1, 33.2, 33.1, 31.4, 31.3, 29.7, 26.8, 26.7, 25.9, 25.6, 22.4 (2), 
20.9; HRMS (ESI+)  m/z calcd for C25H38O4Li [M+Li]: 403.2848, found: 403.2851. 
 
Synthesis of simplified β-lactone cores (±)-18, (±)-19, and (±)-20 derived from t-butyl ester 
(±)-7. 
 
Aldehyde acid (±)-2.71. i) (t-butyl ester deprotection) A solution of ester (±)-2.6 (3.0 g, 7.5 
mmol, 1.0 equiv) in CH2Cl2 (100 mL) was cooled to 0 °C after which TFA (16.0 mL, 150 mmol, 
20.0 equiv) was added, dropwise via syringe. The reaction was allowed to warm to room 
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temperature and proceed until TLC indicated complete consumption of starting material. The 
reaction mixture was concentrated in vacuo to afford a dark brown oil. Purification of the crude 
product by flash chromatography  (SiO2 0 → 30% EtOAc/hexanes) provided 2.4 g (93%) of the 
corresponding carboxylic acid as a brown oil: Rf = 0.50 (1:1-EtOAc:hexanes); 
1
H-NMR (500 
MHz, CDCl3) δ 7.35-7.28 (m, 5H), 4.88 (dt, J = 10.0, 1.0 Hz, 1H), 4.43 (dd, J = 15.5, 12.0 Hz, 
2H), 3.48 (dd, J = 9.0, 3.0 Hz, 1H), 3.23 (dd, J = 9.0, 6.5 Hz, 1H), 2.49-2.39 (m, 3H), 2.34-2.24 
(m, 3H), 2.23-2.18 (ddd, J = 13.5, 9.0, 2.5 Hz, 1H), 1.87-1.76 (m, 2H), 1.73 (d, J = 1.0 Hz, 3H), 
1.71-1.61 (m, 2H), 1.54 (d, J = 1.0 Hz, 3H),  O-H proton not observed; 
13
C-NMR (125 MHz, 
CDCl3) δ 212.1, 179.1, 138.5, 134.6, 128.5(2), 127.7,127.6(2), 126.5, 73.3, 72.6, 53.6, 45.9, 
42.7, 41.6, 32.1, 30.5, 25.9, 21.8, 18.7; IR (thin film) 3339, 3031, 2978, 1732, 1711, 1448, 1362 
cm
-1
; HRMS (ESI+) C21H28O4Li [M+Li]
+
: 351.2148. Found: 351.2143. 
ii) (ozonolysis) A solution of the intermediate carboxylic acid (1.40 g, 4.06 mmol, 1.0 equiv) 
was dissolved in a mixed solvent system of MeOH/CH2Cl2 (1:3, 6 mL/ 18 mL) and cooled to -78 
°C. Ozone was bubbled through the reaction solution until a blue color persisted. Excess ozone 
was removed by blowing N2 gas into the solution with stirring for 10 min. Dimethylsulfide (3.0 
mL, 40.6 mmol, 10.0 equiv) was added by syringe at -78 °C and the reaction was slowly warmed 
to ambient temperature (23 °C) overnight to insure complete reduction of the ozonide. 
Purification by flash chromatography (SiO2 0 → 60% EtOAc/hexanes) gave 790 mg (61%) of 
aldehyde acid (±)-2.71 as a colorless oil: Rf = 0.32 (1:1-EtOAc:hexanes); IR (thin film) 3410, 
3037, 2937, 2860, 2724, 1776, 1711, 1456, 1095 cm
-1
; 
1
H-NMR (500 MHz, CDCl3) δ 9.63 (d, J 
= 4.0 Hz, 1H), 7.36-7.27 (m, 5H), 4.43 (dd, J = 22.0, 12.0, Hz, 2H), 3.45 (dd, J = 9.5, 4.5 Hz, 
1H), 3.31 (dd, J = 9.5, 7.0 Hz, 1H), 2.73 (ddd, J = 11.5, 9.0, 2.5 Hz, 1H), 2.54-2.33 (m, 7H), 2.14 
(ddd, J = 13.0, 8.5, 4.0 Hz, 1H), 1.91-1.84 (m, 1H), 1.65-1.55, 196 (m, 1H), O-H proton not 
observed; 
13
C-NMR (125 MHz, CDCl3) δ 209.7, 200.7, 179.0, 137.7, 128.6(2), 127.9, 127.8(2), 
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73.4, 72.5, 59.1, 46.7, 40.6, 38.7, 31.5, 29.2, 22.1; HRMS (ESI–) Calcd for C18H21O5 [M-H]
- 
: 
317.1389. Found: 317.1375. 
 
β-lactones (±)-2.5 and (±)-2.5’. To an oven-dried round-bottomed flask, modified Mukaiyama’s 
reagent (1.48 g, 4.2 mmol, 3.0 equiv) was added and azeotroped with xylenes in vacuo. It was 
then dissolved in CH2Cl2 (30.0 mL) and Et3N (1.0 mL, 7.1 mmol, 5.0 equiv) was added. A 
separate solution of aldehyde acid (±)-2.71 (450 mg, 1.4 mmol, 1.0 equiv) was prepared in 
CH2Cl2 (10.0 mL) and was subsequently added via syringe pump over 1 h. Purification (SiO2 0 
→ 30% EtOAc/hexanes) provided a 1:3 mixture of diastereomeric -lactones (±)-2.5 (9%, 2.8 
mg) and (±)-2.5’ (30%, 9.1 mg).  
 
Benzyl ether tricyclic -lactone (±)-2.5.  hexanes:EtOAc (1:1) Rf = 0.52 (2:3-EtOAc/hexanes); 
1
H-NMR (500 MHz, CDCl3): δ 7.39-7.31 (m, 5H), 5.17 (app d J = 3.5 Hz, 1H), 4.56, 4.47 (ABq, 
J = 12.0 Hz, 2H), 3.96 (dd, J = 8.0, 3.5 Hz, 1H), 3.53 (dd, J = 9.5, 4.5 Hz, 1H), 3.53 (dd, J = 9.0, 
4.5 Hz, 1H), 3.01 (overlapping ddd, J = 13.0, 6.5, 6.5 Hz, 1H), 2.60 (dd, J = 12.0, 9.0 Hz, 1H), 
2.48-2.41 (m, 1H), 2.38-2.32 (m, 2H), 2.12-2.08 (m, 1H), 1.96 (overlapping ddd, J = 13.0, 13.0, 
8.0 Hz, 1H), 1.63-1.58 (m, 2H). 
13
C-NMR (125 MHz, CDCl3) δ 209.9, 169.8, 137.8, 128.7(2), 
128.1, 127.8(2), 79.0, 73.7, 73.2, 54.9, 49.1, 48.2, 37.1, 33.3, 29.9, 28.9; IR (thin film) 2939, 
2865, 1826, 1711, 1619 cm
-1
; HRMS (ESI+) Calcd for C18H21O4 [M+H]
+
: 301.1440. Found: 
301.1426. 
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Diastereomeric benzyl ether tricyclic -lactone (±)-2.5’: hexanes:EtOAc (1:1) Rf = 0.66 (1:1-
EtOAc/hexanes); 
1
H-NMR (500 MHz, CDCl3) δ 7.37-7.28 (m, 5H), 4.95 (app t, J = 4.0 Hz, 1H), 
4.52, 4.48 (ABq, J = 12.0 Hz, 2H), 3.87 (dd, J = 8.0, 3.5 Hz, 1H), 3.59 (dd, J = 9.5, 4.5 Hz, 1H), 
3.50 (dd, J = 9.5, 5.5 Hz, 1H), 2.82-2.76 (overlapping ddd, J = 12.5, 12.5, 5.5 Hz, 1H), 2.42-2.39 
(m, 2H), 2.33-2.26 (m, 1H), 2.14 (overlapping ddd, J = 16.5, 16.5, 5.5, 2H), 1.82 (ddd, J = 14.0, 
12.0, 8.0, Hz, 1H), 1.75-1.64 (m, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 209.2, 170.8, 138.1, 
128.6(2), 127.9, 127.7(2), 76.1, 73.4, 71.9, 54.5, 51.9, 50.2, 40.6, 37.0, 30.5, 24.8; IR (thin film): 
3030, 2928, 2863, 1824, 1717, 1453, 1119 cm
-1
;
 
HRMS (ESI+) Calcd for C18H21O4 [M+H]
+
: 
301.1440. Found: 301.1435. 
 
Isovaleric ester (±)-3.9. To a solution of (±)-2.5’ (10.0 mg, 0.033 mmol, 1.0 equiv) in EtOH (2 
mL), was added Pd(OH)2 (2.8 mg, 20 wt%, 0.0019 mmol, 0.05 equiv). The contents of the flask 
were then evacuated and flushed with H2 from a balloon three times consecutively and the 
reaction was then allowed to proceed with vigorous stirring until TLC indicated complete 
consumption of starting materials. The reaction mixture was then passed over a pad of Celite, 
washed with EtOH, and the crude filtrate was concentrated in vacuo. The material was carried on 
directly without further purification. 
To primary alcohol A5 in CH2Cl2 (2.68 mL) at 0 °C, Et3N (65 µL, 0.468 mmol, 3.5 equiv) was 
added followed by the dropwise addition of isovaleryl chloride (41 µL, 0.334 mmol, 2.5 equiv). 
The reaction was allowed to proceed until TLC indicated the reaction’s completion. Purification 
utilized preparatory TLC in 30% EtOAc/hexanes developed three times and afforded 3.1 mg 
127 
 
(32% over two steps) of the desired isovaleric ester (±)-3.9. 
1
H NMR (500 MHz, CDCl3): δ 5.01 
(app t, J = 3.5, 3.5 Hz, 1H), 4.30 (dd, J = 11.5, 5.0 Hz, 1H), 3.99 (dd, J = 11.5, 6.0 Hz, 1H), 3.92 
(dd, J = 8.0, 3.5 Hz, 1H), 2.77 (overlapping ddd, J= 11.0, 11.0, 5.0 Hz, 1H), 2.43 (dd, J = 9.0, 
4.5 Hz, 2H), 2.40-2.32 (m, 1H), 2.21-2.14 (m, 4H), 2.10-2.02 (m, 1H), 1.89-1.82 (m, 1H), 1.62-
1.53 (m, 2H), 0.94 (overlapping doublets, J = 7.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3): δ 
208.4, 172.9, 170.2, 75.6, 65.4, 54.5, 52.1, 50.1, 43.2, 40.3, 36.2, 30.1, 25.6, 24.6, 22.4 (2); IR 
(thin film): 2961, 2925, 1827, 1720 cm
-1
; HRMS (ESI+) Calcd for C18H20O4Li [M+Li]: 
301.1627. Found: 301.2064. 
 
Alkynyl alcohol (±)-4.17.  Primary alcohol (±)-3.13 (0.131 g, 0.299 mmol, 1 equiv) was 
dissolved in CH2Cl2 (0.3 mL).  To this solution, DMAP (3.7 mg, 0.029 mmol, 10 mol%) was 
added followed by 5-hexynoic acid (33 μL, 0.299 mmol, 1 equiv).  After cooling to 0 ˚C, DCC 
(68 mg, 0.33 mmol, 1.1 equiv) was added and the reaction was allowed to gradually warm to 
room temperature and proceed overnight.  The next day, the white precipitate that had formed 
was removed by filtration through a Celite plug which was subsequently washed with CH2Cl2 (2 
mL).  The organics were washed with 0.5 N HCl (2 x 2 mL) followed by NaHCO3 (2 mL). dried 
(Na2SO4), and concentrated in vacuo.  The resulting product (90%, 0.144 g) was taken on 
directly to the next reaction. 
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Alkynyl probe (±)-4.16. Tertiary alcohol (±)-4.17 (56.6 mg, 0.131 mmol, 1.0 equiv) was 
dissolved in CH2Cl2 and Et3N and cooled to 0 ˚C.  SOCl2 (40.4 μL, 0.557 mmol, 4.25 equiv) was 
added via microliter syringe and the reaction was allowed to proceed overnight.  The next day it 
was concentrated directly and purified by flash column chromatography. Purification (SiO2 0 → 
30% EtOAc/hexanes) provided alkynyl probe (±)-4.16 (78%, 4.2 mg). 
Alkynyl probe (±)-4.16.  hexanes:EtOAc (3:1) Rf = 0.7; 
1
H-NMR (500 MHz, CDCl3): δ 5.56 
(app s, 1H), 4.95 (app t, J = 4.0 Hz, 1H), 4.23 (dd, J = 11.5, 5.0 Hz, 1H), 3.98 (dd, J = 11.0, 6.0 
Hz, 1H), 3.83, (dd, J = 8.5, 4.0 Hz, 1H), 2.45 (app t, J = 8.0 Hz, 2H), 2.33-2.23 (m, 6H), 2.20-
2.17 (m, 1H), 2.12-2.06 (m, 1H), 1.95 (app t, J = 2.5 Hz, 2H), 1.89-1.82 (m, 6H), 1.75-1.74 (m, 
2H), 1.32-1.21 (m, 2H), 1.12 (s, 3H), 0.89 (s, 3H), 0.76 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 
173.1, 171.2, 145.3, 119.3, 83.2, 74.6, 69.2, 66.7, 55.0, 49.7, 49.2, 39.9, 39.8, 39.4, 38.0, 33.5, 
32.8, 32.2, 31.8, 31.4, 30.4, 30.1, 29.7, 23.5, 19.8, 17.8; IR (thin film): 3538, 3310, 1821, 1724 
cm
-1
; HRMS (ESI+) Calcd for C26H37O4 [M+H]
+
: 412.2614. Found: 413.2511. 
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Figure A1 Single Crystal X-ray Crystallographic Data for Ester (±)-2.77. 
CCDC 970423 ((±)-13) contains the supplementary crystallographic data for this 
compound. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
 
 
Table A5.  Crystal data and structure refinement for DRB_NH_130228_G_IE. 
Identification code  drb 
Empirical formula  C32 H56 O5 
Formula weight  520.77 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 17.128(3) Å = 90°. 
 b = 10.413(2) Å = 119.543(12)°. 
 c = 20.540(4) Å  = 90°. 
Volume 3187.1(10) Å3 
Z 4 
Density (calculated) 1.085 Mg/m3 
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Table A5 Continued. 
Absorption coefficient 0.556 mm-1 
F(000) 1152 
Crystal size 0.05 x 0.04 x 0.01 mm3 
Theta range for data collection 2.97 to 60.00°. 
Index ranges -19<=h<=19, -11<=k<=11, -23<=l<=22 
Reflections collected 19254 
Independent reflections 4735 [R(int) = 0.1156] 
Completeness to theta = 60.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9945 and 0.9727 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4735 / 0 / 346 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0624, wR2 = 0.1450 
R indices (all data) R1 = 0.1249, wR2 = 0.1721 
Extinction coefficient 0.0017(2) 
Largest diff. peak and hole 0.274 and -0.232 e.Å-3 
 
Table A6.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for DRB_NH_130228_G_IE.  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
________________________________________________________________________________  
 x y z U(eq) 
______________________________________________________________________________ 
O(1) 4527(2) 1502(2) 1639(1) 34(1) 
O(2) 1637(2) 1084(2) -1244(1) 40(1) 
O(3) 218(2) 1662(4) -1637(2) 79(1) 
O(4) 4330(2) -1366(2) 3568(1) 40(1) 
O(5) 3194(2) 52(2) 3248(1) 39(1) 
C(1) 5576(2) -295(3) 1764(2) 32(1) 
C(2) 5945(2) -119(4) 2615(2) 36(1) 
C(3) 6960(2) -303(3) 3163(2) 35(1) 
C(4) 7498(3) 473(4) 2887(2) 40(1) 
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Table A6 Continued.   
________________________________________________________________________________  
 x y z U(eq) 
______________________________________________________________________________ 
C(5) 7208(2) 168(4) 2078(2) 40(1) 
C(6) 6212(2) 446(4) 1564(2) 36(1) 
C(7) 5553(2) -1709(3) 1540(2) 39(1) 
C(8) 7261(3) -1712(4) 3278(2) 47(1) 
C(9) 7138(3) 200(4) 3924(2) 49(1) 
C(10) 4585(2) 306(3) 1300(2) 31(1) 
C(11) 4364(2) 624(3) 496(2) 33(1) 
C(12) 3438(2) 1206(3) 23(2) 36(1) 
C(13) 2700(2) 328(3) -31(2) 33(1) 
C(14) 2858(2) -39(3) 745(2) 33(1) 
C(15) 3826(2) -578(3) 1255(2) 32(1) 
C(16) 1782(2) 936(4) -494(2) 39(1) 
C(17) 809(3) 1424(4) -1774(2) 45(1) 
C(18) 721(2) 1430(4) -2532(2) 46(1) 
C(19) -210(3) 1766(4) -3164(2) 55(1) 
C(20) -406(3) 3192(5) -3154(3) 82(2) 
C(21) -314(3) 1380(6) -3905(3) 88(2) 
C(22) 2176(2) -1028(3) 675(2) 32(1) 
C(23) 1520(2) -948(3) 841(2) 39(1) 
C(24) 911(3) -2068(4) 736(2) 46(1) 
C(25) 1297(3) 239(4) 1142(2) 51(1) 
C(26) 3917(2) -1053(3) 2002(2) 32(1) 
C(27) 3866(3) 9(3) 2500(2) 37(1) 
C(28) 3836(2) -525(4) 3161(2) 36(1) 
C(29) 3010(3) -267(4) 3860(2) 48(1) 
C(30) 2246(3) 647(4) 3708(3) 54(1) 
C(31) 2698(3) -1647(4) 3779(3) 67(1) 
C(32) 3831(3) 12(5) 4606(2) 68(1) 
________________________________________________________________________________  
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Cell culture 
 
K562 (chronic myelogenous leukemia (CML)) cell line was cultured in RPMI-1640 medium 
(Sigma R7509) supplemented with 2 mM L-glutamine and 10% heat-inactivated FCS. Medium 
used for MTT assay did not contain Phenol Red. Cells were incubated at 37 °C in a humidified 
atmosphere containing 5 % CO2.  
 
Cytotoxicity assay (MTT assay)
[3]
 
Cells at exponential phase were used for the assay. Cells were diluted with a fresh culture 
medium to the concentration 1.6∙105 cells/mL. 50 µL cell suspension were plated in a 96-well 
round-bottom transparent plate, so that cell density was 8∙103 cells per well. Also, wells not 
containing cells were included in the assay to subtract blank absorbance resulting from medium, 
MTT and a lysis buffer. Directly before the treatment, compounds 2.1, 2.5, 2.5’, 2.79, 3.8 and 
3.9 were diluted 1:49 (v/v) from DMSO stocks (stored at -80° C) with a pre-warmed culture 
medium. 50 µL testing compound solution were added to the 50 µL cells in triplicate wells. Final 
volume in each well was 100 µL, cell density was 8 x10
4
 cells/mL and final compound 
concentration ranged between 0.01 and 1000 μM. After 24 h exposure, 20 µL MTT solution (5 
mg/mL in PBS, sterile filtered) [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(Sigma M5655)] were added to each well and mixed well into the medium. The plates were 
incubated at 37 °C, 5% CO2 for 4 h in the dark to allow MTT to be metabolized. Then, 50 µL 
‘triplex lysis solution’ (10% SDS (w/v), 5% isobutanol (v/v), 0.012 M HCl in distilled H2O) 
were added to each well and mixed well into the medium. The plates were incubated overnight 
(14-16 h) at 37 °C, 5% CO2. The complete dissolution of the formazan salt (metabolic product of 
                                                          
3
 C. Qing, Z. H. Miao, L. J. Tong, J. S. Zhang, J.Ding Acta Pharmacol. Sin. 2003, 24, 415-421. 
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MTT) was checked under the microscope and the optical density was measured at 570 nm by a 
TECAN Infinite® M200 Pro. All biological experiments were performed with three independent 
replicates. Average blank absorbance (medium, MTT solution and lysis buffer) was subtracted 
from average absorbance of wells containing cells. Percent inhibition of metabolic activity (cells 
viability) was calculated as a fraction of control (cells treated only with the DMSO (vehicle)). 
IC50 values (when applicable) were calculated using sigmoidal dose response curve fitting 
algorithm in OriginPro 8.5.1 (OriginLab Corporation).  
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Figure A2. Dose response fit of cell metabolic activity (MTT assay) upon treatment with 
different concentrations of spongiolactone and derivatives, (+)-2.1, (+)-2.5, (±)-2.5’, (±)-3.8, (±)-
2.79 and (±)-3.9, to determine IC50 values. 
 
2.1 (μM) 2.5 (μM) 
 
2.5’ (μM) 
 
3.8 (μM) 
 
3.9 (μM) 
 
2.79 (μM) 
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Phosphonate ester A4. To a pre-weighed mixture of phenol 5.43 (1.50 g, 5.92 mmol, 1.0 equiv) 
and phosphonate ester bromide 5.44 (2.30, 7.7 mmol, 1.3 equiv) in DMF (16 mL), K2CO3 (1.3 g, 
9.48 mmol, 1.6 equiv) was added.  The reaction was heated in an oil bath to 65 °C and kept at 
this temperature for 18 h. The reaction was quenched with saturated NH4Cl (16 mL) and water 
(10 mL) was added to completely dissolve all solids.  The reaction mixture was then extracted 
with EtOAc (3 x 50 mL).  The combined organics were washed with water (100 mL) and brine 
(100 mL), dried with Na2SO4, and concentrated in vacuo to provide 2.80 g (quant) of 
phosphonate ester A4 as a brown oil which was taken on directly without further purification: 
TLC (EtOAc:hexanes, 1:1 v/v): Rf  = 0.2 ; 
1
H NMR (500 MHz, CDCl3):  δ 7.16 (d, J = 9.0 Hz, 
2H), 6.81 (d, J = 9.0 Hz, 2H), 5.43 (app d, J = 18.0 Hz, 1H), 4.66 (br s, 1H), 4.06-4.00 (m, 4H), 
3.89 (t, J = 6.5 Hz, 2H), 3.75 (br m, 2H), 1.73-1.66 (m, 4H), 1.61-1.56 (m, 2H), 1.43-1.39 (m, 
14H), 1.28 (t, J = 7.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3): 158.6, 156.2, 129.5, 127.8 (2), 
114.8 (2), 79.9, 67.9, 67.0, 61.6 (2), 56.5, 30.3 (JC-P=17.0 Hz), 29.1, 28.5 (3), 25.7 (t, JC-P = 62.5 
Hz), 22.5, 22.4, 16.6 (2); 
31
P NMR (202.4 MHz, CDCl3): 32.5; IR (thin film): 3428, 2982, 1712, 
1514, 1250 cm
-1
; HRMS (+ESI) m/z calcd for C23H39NNaO7P [M+Na]
+
 :   496.2440, found: 
496.2431. 
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Alcohol 5.45. Phosphonate ester A4 (2.80 g, 5.92 mmol, 1.0 equiv) was dissolved in 4N HCl in 
1,4-dioxane (29.5 mmol, 7.38 mL, 5.0 equiv) and stirred at 23 °C for 3 hours at which point TLC 
showed complete consumption of starting material.  The reaction was diluted with EtOAc (5 
mL) and the aqueous layer was basified with 1N NaOH solution to achieve a pH of 10.  The 
organic layer was separated and the aqueous layer was further extracted with EtOAc (2 x 10 
mL).  The combined organic layers were washed with brine (30 mL), dried with Na2SO4, and 
concentrated in vacuo to cleanly provide  amino alcohol 5.45 (2.2 g, quant) as a brown oil which 
was taken on without further purification: TLC (EtOAc): Rf  = 0.1 ; 
1
H NMR (500 MHz, 
CDCl3):  δ 7.20 (d, J = 8.5 Hz, 2H), 6.81 (d,  J= 8.5 Hz, 2H), 4.06-4.00 (m, 4H), 3.88 (t, J = 6.5 
Hz, 2H), 3.68-3.66 (m, 1H), 3.58 (app t, J = 7.0 Hz, 1H), 3.53 (app t, J = 9.5 Hz, 1H), 2.92 (br s, 
2H), 1.74-1.65 (m, 4H), 1.61-1.50 (m, 2H), 1.41-1.38 (m, 5H), 1.27 (t, J = 7.0 Hz, 6H); 
13
C 
NMR (125 MHz, CDCl3): 158.6, 133.8, 127.8 (2H), 114.7 (2), 67.9, 67.7, 61.6, 61.5, 56.9, 30.3 
(JC-P=17.0 Hz), 29.1, 25.7 (t, JC-P = 71.5 Hz), 22.5, 22.4, 16.6 (2); 
31
P NMR (202.4  MHz, 
CDCl3): 32.4; IR (thin film): 3419, 2933, 1612, 1517, 1247, 1056 cm
-1
; HRMS (+ESI) m/z calcd 
for C18H33NO5P [M+H]
+
 : 374.2096, found: 374.2112.   
 
 
 
Alcohol 5.45.
1
 Amino alcohol 5.45 (2.20 g, 5.92 mmol, 1.0 equiv) was weighed into a high 
pressure vessel to which chlorobenzene (2.85 mL), iPr2Net (1.34 mL, 7.7 mmol, 3.9 equiv), and 
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1-chlorobenzothiazole (0.27 mL, 2.09 mmol, 1.06 equiv).  The reaction was heated in an oil bath 
to 135 °C and kept at this temperature for 18 h. Purification by flash column chromatography 
(SiO2, 10 → 100% EtOAc/hexanes, 0 → 10% MeOH/CH2Cl2) gave 0.269 g (27%) of alcohol 
5.46 as a brown oil: TLC (MeOH:CH2Cl2, 1:9 v/v): Rf  = 0.6 ; 
1
H NMR (500 MHz, CDCl3):  δ 
7.43 (dd, J = 8.0, 3.5 Hz, 1H), 7.23 (d, J = 8.5 Hz, 2H), 7.19 (app t, J = 7.0 Hz, 1H), 7.14 (d, J = 
8.5 Hz, 1H), 6.98 (app t, J = 7.5 Hz, 1H), 6.78 (d, J = 8.5 Hz, 2H), 4.70 (dd, J = 7.5, 4.0 Hz, 1H), 
4.05-4.00 (m, 4H), 3.85 (t, J = 7.0 Hz, 2H), 3.80 (dd, J = 11.5, 7.5 Hz, 1H), 3.57 (app t, J = 6.5 
Hz, 1H), 1.70-1.64 (m, 4H), 1.58-1.52 (m, 2H), 1.41-1.38 (m, 6H), 1.27 (t, J = 7.0 Hz, 6H); 
13
C 
NMR (125 MHz, CDCl3): 167.9, 158.8, 156.3, 151.7, 130.7, 128.2 (2), 125.9, 121.6, 120.8, 
118.8, 114.7 (2), 67.8, 66.9, 62.6, 61.6 (2), 30.3 (d, JC-P=17.0 Hz), 29.0, 28.4, 25.6 (t, JC-P = 63.4 
Hz), 22.4 (d, JC-P = 5.0 Hz), 16.5 (2); IR (thin film): 3389, 3252, 2936, 1712, 1244 cm
-1
; HRMS 
(+ESI) m/z calcd for C25H36N2O5P [M+H]
+
 : 507.2083, found: 507.2107. 
 
 
 
Phosphonate ester, (+)-benzotetramisole 5.47. Alcohol 5.46 (0.305 g, 0.601 mmol, 1.0 equiv) 
was dissolved in CH2Cl2 (6.0 mL) and Et3N (0.25 mL, 1.80 mmol, 3.0 equiv) and cooled to 0 °C 
in an ice bath.   Methanesulfonyl chloride (70 µL, 0.90 mmol, 1.5 equiv) was added dropwise 
and the reaction was kept at 0 °C for 30 minutes.  The ice bath was removed and the reaction 
warmed to room temperature and proceeded for 2 hours.  After this time, MeOH (0.25 mL, 6.17 
mmol, 10.3 equiv) was added followed by Et3N (0.25 mL, 1.80 mmol, 3.0 equiv) and the 
reaction was heated to reflux and proceeded overnight.  Purification by flash column 
chromatography (SiO2, 10 → 100% EtOAc/hexanes, 0 → 10% MeOH/CH2Cl2) gave 0.208 g 
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(71%) of phosphonate ester 5.47 as a brown oil: TLC (MeOH:CH2Cl2, 1:9 v/v): Rf  = 0.6 ; [α]D
20
 
= +63.3 (c = 0.17, CHCl3); 
1
H NMR (500 MHz, CDCl3):  7.23 (d, J = 7.5 Hz, 1H), 7.19 (d, J = 
7.0 Hz, 2H), 7.11 (app t, J = 7.5 Hz, 1H), 6.90 (app t, J = 8.0 Hz, 1H), 6.80 (d, J = 8.5 Hz, 2H), 
6.61 (d, J = 8.0 Hz, 1H), 5.53 (app t, J = 9.5 Hz, 1H), 4.18 (app t, J = 10.0 Hz, 1H), 4.07-3.99 
(m, 4H), 3.86 (t, J = 6.0 Hz, 2H), 3.61 (app t, J = 8.5 Hz, 1H), 1.69-1.63 (m, 4H), 1.58-1.52 (m, 
2H), 1.38-1.35 (m, 6H), 1.24 (t, J = 7.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3): 166.5, 158.5, 
136.9, 134.7, 127.5 (2), 126.6, 123.1, 121.5, 114.6 (2), 108.6, 74.4, 67.7, 61.3 (2), 52.5, 30.2 (d, 
JC-P=16.9 Hz), 28.9, 28.8, 25.5 (t, JC-P = 70.0 Hz), 22.3 (2), 16.4 (2); IR (thin film): 2939, 1757, 
1603, 1511, 1472, 1244 cm
-1
; 
31
P NMR (202.4  MHz, CDCl3): 32.4; HRMS (+ESI) m/z calcd for 
C25H34N2O4PS [M+H]
+
 : 489.1977, found: 489.1998. 
 
 
 
 
Phosphonic acid 5.48. To a solution of phosphonate ester (0.204 g, 0.420 mmol, 1.0 equiv) in 
CH2Cl2 (4.2 mL) at 23 °C was added trimethylsilyl bromide (0.276 mL, 2.10 mmol, 5.0 equiv). 
The reaction was allowed to proceed overnight after which time TLC indicated complete 
consumption of starting material.  The reaction was concentrated, taken up in MeOH (3 mL), and 
stirred for 3 h.  After this time, it was concentrated in vacuo and taken up in CHCl3 (5 mL) and 
water (5 mL). A brown, viscous oil layer formed which was separated from both the CHCl3 and 
water layers and dried in vacuo to provide pure phosphonic acid 5.48.  TLC (MeOH, 1:1 v/v): Rf  
= 0.1; 
1
H NMR (500 MHz, CDCl3): δ7.59 (dd, J = 7.5, 1.0 Hz, 1H), 7.34 (td, J = 7.0, 1.0 Hz, 1 
H), 7.20-7.18 (m, 2H), 7.15 (d, J = 9.0 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H), 5.78 (dd, J = 11.0, 8.5 
Hz, 1H), 4.84-4.79 (m, 1H), 4.12 (dd, J = 10.5, 8.5 Hz, 1H), 3.74 (t, J = 6.5 Hz, 1H), 1.55-1.42 
139 
 
(m, 6H), 1.30-1.20 (m, 4H); 
13
C NMR (125 MHz, CDCl3/CD3OD): 169.5, 160,1, 137.5, 134.2, 
128.0 (2), 127.4, 125.7, 124.4, 115.4 (2), 112.6, 68.0, 66.7, 53.5, 49.7, 30.2, 28.9 (2), 25.6, 22.5; 
IR (thin film): 3422, 2933, 1612, 1514, 1466, 1247 cm
-1
; 
31
P NMR (202.4  MHz, CDCl3): 17.7; 
HRMS (+ESI) m/z calcd for C21H26ClN2O4PS [M-Cl]
+
 : 433.1351, found: 433.1357. 
Magnetite preparation. 
 
FeCl3·6 H2O (2.335 g, 8.6 mmol, 2.0 equiv) and FeCl2·4 H2O (0.860 g, 4.3 mmol, 1.0 equiv) 
were weighed into a 250 mL round-bottom flask and dissolved in distilled water (80 mL).  The 
solution was heated to 90 ˚C and evacuated/flushed with N2 for 5 cycles.  NH4OH (25%, 3.0 mL) 
was added, dropwise, with vigorous stirring during which time a black precipitate formed.  
Magnetite formation was allowed to proceed for 1 hour after which time magnetic decantation 
with a neodymium magnet was used to isolate the product.  The MNP were washed with distilled 
water (4 x 50 mL) until the pH of the supernatant was neutral.  Finally, the magnetite was 
washed with EtOH (2 x 50 mL) and dried in vacuo overnight to provide magnetite (1.98 g, 60% 
yield) as a fine, black powder. 
 
 
 
Loading of catalyst by sonication. 
 
A solution of phosphonic acid-BTM derivative 5.48 (0.1255 g, 0.291 mmol, 1 equiv) was 
prepared in methanol (2.9 mL).  Freshly prepared Fe3O4 (45.0 mg, 0.19 mmol, 0.65 equiv) was 
added and the homogeneous solution was sonicated for 30 minutes at 23 ˚C.  After this time, a 
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neodymium magnet was used to attract the magnetite to the bottom of the vial.  When the 
solution became clear, the supernatant was removed by pipette.  The vial was removed from the 
magnet and the MNP were washed with MeOH (3 mL) to remove unreacted catalyst.  The 
washing/magnetic decantation process was repeated for a total of three times and the final MNP 
were dried in vacuo overnight. IR (thin film): 2860, 1606, 1511, 1469, 1244, 983 cm-1. 
 
Transmission Electron Microscopy (TEM) of 5.59. 
 
 
Determination of catalyst loading. 
 
A 52.06 mM stock solution of NaHPO4 was prepared by adding 73.9 mg (0.52 mmol) of 
NaHPO4 to a volumetric flask and diluting to a final volume of 10 mL.  Separately, phosphonic 
acid-BTM derivative 5.48  (8.1 mg, 0.19 mmol) was dissolved in concentrated HCl (12 M, 0.2 
mL).  To this solution, NaOH (12 M, 0.2 mL) was added to adjust the pH of the solution to 13 
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causing a salt to precipitate which was removed by filtration through Celite in a disposable 
pipette.  The Celite and filter cake were rinsed with MeOH (0.2 mL) and enough water to give a 
final volume of 1 mL.   
 
An NMR sample was then prepared with the following components: 50 μL of NaHPO4 stock 
solution (52.06 mM), 50 μL of NaOH (12 M), 500 μL of MNP solution, and 22 μL of D2O.  
Catalyst loading was determined to be 0.067 mmol catalyst/1 g of sample by utilizing the relative 
31
P peak intensities from the MNP and NaHPO4. 
 
 
 
Polyisobutylene ether 5.56. Polyisobutylene bromide (3.32 g, 3.16 mmol, 2.0 equiv) was 
weighed and dissolved in heptane (8 mL).  Phenol 5.43 (0.40 g, 1.58 mmol, 1.0 equiv) was 
added to the polymer solution along with DMF (8 mL) followed by K2CO3 (1.44 g, 3.16 mmol, 
2.0 equiv) and tetrabutylammonium bromide (0.50 g, 1.58 mmol, 1.0 equiv).  The reaction was 
heated in an oil bath to 80 °C and kept at this temperature for 18 h. Upon cooling, the heptane 
layer was separated.  Water (50 mL) was added to dissolve all solids in the aqueous layer which 
was further extracted with hexanes (3 x 50 mL).  The combined organics were washed with 
water (100 mL) and brine (100 mL), dried with Na2SO4, and concentrated in vacuo to provide 
0.49 g (26%) of PIB-ether 5.56.  Purification by MPLC (0 → 100% EtOAc/hexanes): TLC 
(EtOAc:hexanes, 3:7 v/v): Rf  = 0.5 ; 
1
H NMR (500 MHz, CDCl3):  δ 7.16 (d, J = 9.0 Hz, 2H), 
6.83 (d, J = 8.5 Hz, 2H), 5.16 (br s, 1H), 4.68 (br s, 1H), 3.76-3.72 (m, 3H), 3.57 (app t, J = 8.0 
Hz, 1H), 1.44-1.36 (m), 1.13-1.02 (m); 
13
C NMR (125 MHz, CDCl3): 159.0, 156.3, 131.3, 128.1, 
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127.4, 115.1, 114.6, 80.0, 67.2, multiple peaks between 59.6 and 58.3, 56.9, 49.8, multiple peaks 
between 38.3 and 28.4, 20.5; IR (thin film): 3431, 2964, 1682, 1511, 1387, 1244 cm
-1
. 
 
PIB Amino Alcohol 5.56. PIB ether 5.56 (0.49 g, 0.41 mmol, 1.0 equiv) was weighed and 
dissolved in 1,4-dioxane (3 mL).  To this, 4N HCl in 1,4-dioxane (6.6 mL) was added at 23 ˚C.  
The reaction was allowed to proceed overnight. After this time, the starting material was 
completely consumed as determined by TLC, the reaction was concentrated in vacuo to provide 
0.45 g (quant) of amino alcohol 5.57 which was taken on directly as the hydrochloride salt to the 
next reaction. TLC (EtOAc:hexanes, 3:7 v/v): Rf  = 0.05; 
1
H NMR (500 MHz, CDCl3):  δ 7.20 
(d, J = 7.5 Hz, 2H), 6.84 (d, J = 8.0 Hz, 2H), 3.96 (br s, 1H), 3.73 (app t, J = 8.0 Hz, 1H), 3.67 
(br m, 1H), 3.58 (app t, J = 8.0 Hz, 1H), 3.50 (br s, 1H), 1.39-1.30 (m), 1.1-0.96 (m); 
13
C NMR 
(125 MHz, CDCl3): 158.8, 134.5, 127.9, 127.3, 114.9, 114.4, 74.7, 74.3, multiple peaks between 
59.6 and 56.8, 49.8, multiple peaks between 38.3 and 29.3, 20.5;
 
IR (thin film): 3383, 2951, 
1745, 1615, 1511, 1469, 1366, 1238 cm
-1
. 
 
Aminobenzothiazole 5.58. Amino alcohol hydrochloride salt 5.57 (0.45 g, 0.41 mmol, 1.0 
equiv) was weighed, dissolved in CH2Cl2 (2 mL) and transferred to a sealed pressure tube. The 
solvent was evaporated with a stream of N2.  Chlorobenzene (0.5 mL) was added followed by 
Hünig’s base (0.28 mL, 1.6 mmol, 3.9 equiv) and the dropwise addition of 2-
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chlorobenzothiazole (70 μL, 0.43 mmol, 1.06 equiv).  N2 was blown over the reaction mixture 
for 5 minutes after which time the tube was sealed and heated in an oil bath to 135 ˚C for 16h.  
After this time, the reaction was concentrated and directly loaded onto silica for purification.  
The aminobenzothiazole 5.58 desired product was isolated as a 1:1 mixture of inseparable 
diastereomers (0.33 g, 66%) by MPLC purification (SiO2, 0 → 30% MeOH/CH2Cl2): TLC 
(MeOH/CH2Cl2, 1:9 v/v): Rf  = 0.4; 
1H NMR (500 MHz, CDCl3):  δ 7.48 (app t, J = 7.5 Hz, 2H), 
7.26 (d, J = 9.0 Hz, 2H), 7.12 (app t, J = 8.0 Hz, 1H), 7.05 (app t, J = 8.0 Hz, 1H), 6.84 (d, J = 
8.5 Hz, 2H), 4.74 (app t, J = 5.5 Hz, 1H), 3.93-3.88 (m, 2H), 3.74-3.71 (m, 1H), 3.58-3.55 (m, 
1H), 1.41-1.33 (m, H), 1.10-0.98 (m, H); 
13
C NMR (125 MHz, CDCl3): 168.4, 159.3, 151.4, 
130.5, 130.1, 128.6, 128.4, 127.9, 127.7, 126.4, 125.9, 122.2, 121.5, 121.4, 120.6, 119.9, 118.7, 
115.6, 115.2, 114.7, 74.7, 74.3, 67.2, 62.5, 62.1, multiple peaks from 59.6-56.9, 49.8, multiple 
peaks from 38.3-29.3, 20.5; IR (thin film): 3428, 2951, 1645, 1548, 1508, 1360 cm
-1
. 
 
PIB-BTM 5.59. Aminobenzothiazole 5.58 (0.296 g, 0.25 mmol, 1.0 equiv) was weighed and 
dissolved in CH2Cl2 (1.6 mL) followed by Et3N (0.1 mL, 0.74 mmol, 3.0 equiv).  The resulting 
solution was cooled in a 0 ˚C ice bath for 10 minutes after which time MsCl (30 μL, 0.37 mmol, 
1.5 equiv) was added dropwise.  The reaction was allowed to proceed at 0 ˚C for 30 minutes then 
the ice bath was removed and the reaction warmed to 23 ˚C and continued for 3 h.  After this 
time, MeOH (0.1 mL) was added to quench any remaining MsCl followed by Et3N (0.1 mL). 
The reaction was heated to 45 ˚C and proceeded overnight.  The next day, the reaction was 
concentrated in vacuo and purified directly by MPLC to provide 0.225 g (76%) of PIB-BTM 
5.59.  MPLC purification (SiO2, 0 → 30% MeOH/CH2Cl2): TLC (MeOH/CH2Cl2, 1:9 v/v): Rf  = 
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0.4 ; NMR data is provided for the mixture of diastereomers (1:1 by crude NMR) after 
purification some separation was achieved, providing a final ratio of 2.5:1 for which the NMR 
data is reported; [α]D
20
 = +15.8 (c = 0.17, CHCl3);  
1
H NMR (500 MHz, CDCl3):  δ 7.29 (app d, J 
= 8.5 Hz, 1H), 7.28 (app d, J = 8.0 Hz, 1H), 7.25 (d, J = 8.5, 2H), 7.22 (d, J = 8.5 Hz, 2H), 7.16 
(dt, J = 7.5, 1.0 Hz, 2H), 6.95 (dt, J = 7.5, 1.0 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 9.0 
Hz, 2H), 6.65 (d, J = 7.5 Hz, 2H), 5.60 (dd, J = 8.5, 1.5 Hz, 1H), 4.87 (app t, J = 8.0 Hz, 1H), 
4.67 (app t, J = 9.0 Hz, 1H), 4.22 (app t, J = 9.0 Hz, 1H), 4.14 (dd, J = 7.0, 1.5 Hz, 1H), 3.75 
(dd, J = 5.5, 3.0 Hz, 2H), 3.66 (app t, J = 8.5 Hz, 1H), 3.59 (dd, J = 8.0, 6.5 Hz, 2H), 1.39-1.31 
(m), 1.13-1.02 (m), 1.08-0.97 (m); 
13
C NMR (125 MHz, CDCl3): 166.7, 158.9, 137.2, 134.9, 
128,2, 128.0, 127.4, 127.2, 127.0, 126.4, 123.8, 123.4, 123.0, 122.8, 122.0, 121.2, 115.5, 115.1, 
114.9, 114.5, 108.7, 108.1, 74.7, 74.3, multiple peaks from 59.6-56.9, 52.7, 52.5, 49.8, multiple 
peaks from 38.3-29.3, 20.5;
 
IR (thin film): 3434, 2961, 1639, 1511, 1469, 1369, 1241 cm
-1
. 
 
Typical procedure for kinetic resolution of 1-(1-naphthyl)ethanol (5.50).  A solution of PIB-
BTM 5.59 (4.2 mg, 3.4 μmol, 4mol%) was prepared in heptane (0.6 mL).  1-(1-naphthyl)ethanol 
(5.50) (14.4 mg, 84 μmol, 1.0 equiv) was added followed by PhMe (0.2 mL) and iPr2Net (11 μL, 
63 μmol, 0.75 equiv).  The solution was cooled to 0 ˚C and (EtCO)2O (8 μL, 63 μmol, 0.75 
equiv) was added.  The reaction was allowed to proceed for 2.5 h after which it time it was 
concentrated.  A small aliquot was taken for HPLC analysis and separated using known 
conditions.
2
  To the crude reaction mixture, CH3CN was added and a film formed on the bottom 
of the vial.  The solution was placed on ice for 30 minutes and the CH3CN was removed by 
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pipette.  The remaining 5.59 was washed with more CH3CN (2 x 1 mL) to provide the clean 
catalyst.  By HPLC analysis (OD-H, 10% 
i
PrOH, 0.9 mL/min), the conversion was 52%, ee5.50 = 
97%, ee5.51 = 88%. 
 
 
1.) Birman, V. B.; Li, X.  Org. Lett. 2006, 8, 1351-1354. 
 
2.) Li, X.; Jiang, H.; Uffman, E. W.; Guo, L.; Zhang, Y.; Yang, X.; Birman, V. B.  J. Org. Chem. 
2012, 77, 1722-1737. 
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1
H NMR (500 MHz) and
 13
C NMR (125 MHz) of β-keto enol ether 2.8 in CDCl3 
 
2.8 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of benzyl ether (±)-2.70 in CDCl3 
(±)-2.70 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of cyclohexenone (±)-2.7 in CDCl3 
(±)-2.7 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of tri-substituted cyclohexanone (±)-2.6 in CDCl3 
(±)-2.6 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of homoallylic alcohol (±)-2.74 in CDCl3  
(±)-2.74 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of isovaleric ester (±)-2.77 in CDCl3  
(±)-2.77 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of aldehyde acid (±)-2.73 in CDCl3  
(±)-2.73’ (±)-2.73 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of β-lactone (+)-3.13 in CDCl3 
 
(+)-3.13 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of β-lactone (-)-3.13 in CDCl3
(-)-3.13 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of epimerized (±)-2.73 in CDCl3 
 
(±)-2.73 
 
(±)-2.73 ’ 
157 
 
 
 
 
1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of spongiolactone (+)-2.1 in CDCl3 
(+)-2.1 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of regioisomeric spongiolactone (+)-2.79 in CDCl3 
 
 
(+)-2.79 
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Overlay of 
1
H NMR (500 MHz, CDCl3) of C3’-norspongiolactone (natural, top) and spongiolactone 
(synthetic, bottom) 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of allyl chloride 2.76 in CDCl3 
2.76 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of alkene acid 2.77 in CDCl3 
 
2.77 
162 
 
 
 
 
1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of aldehyde acid (±)-2.73 in CDCl3 
  2.73 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of β-lactone (±)-3.8 in CDCl3 
 
(±)-3.8 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of β-lactone (±)-2.5 in CDCl3 
 
(±)-2.5 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of β-lactone (±)-2.5’ in CDCl3
(±)-2.5’ 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of β-lactone (±)-3.9 in CDCl3 
(±)-3.9 
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1
H NMR (500 MHz) and 
13
C NMR (125 MHz) of alkyne probe (±)-4.16 in CDCl3 
(±)-4.16 
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H NMR (500 MHz) and
 13
C NMR (125 MHz) of A4 in CDCl3 
 
A4 
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1
H NMR (500 MHz) and
 13
C NMR (125 MHz) of 5.45 in CDCl3 
 
5.45 
170 
 
 
 
 
 
1
H NMR (500 MHz) and
 13
C NMR (125 MHz) of 5.46 in CDCl3 
 
5.46 
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1
H NMR (500 MHz) and
 13
C NMR (125 MHz) of 5.47 in CDCl3
 
5.47 
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1
H NMR (500 MHz) and
 13
C NMR (125 MHz) of 5.48 in CDCl3 and CD3OD 
 
 
5.48 
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31
P NMR (202 MHz) of A4 in CD3OD 
 
31
P NMR (202 MHz) of 5.45 in CD3OD 
 
 
 
5.45 
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31
P NMR (202 MHz) of A4 in CD3OD 
 
31
P NMR (202 MHz) of 5.45 in CD3OD 
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IR spectrum of 5.48 
 
 
IR spectrum of 5.49 
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1
H NMR (500 MHz) and
 13
C NMR (125 MHz) of 5.56 in CDCl3 
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(500 MHz) and
 13
C NMR (125 MHz) of 5.57 in CDCl3 
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(500 MHz) and
 13
C NMR (125 MHz) of 5.58 in CDCl3 
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(500 MHz) and
 13
C NMR (125 MHz) of 5.59 in CDCl3 
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WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, 
TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, 
WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, 
FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), 
AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY 
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY 
LIMITED REMEDY PROVIDED HEREIN.  
 Should any provision of this Agreement be held by a court of competent jurisdiction 
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to 
achieve as nearly as possible the same economic effect as the original provision, 
and the legality, validity and enforceability of the remaining provisions of this 
Agreement shall not be affected or impaired thereby.  
 The failure of either party to enforce any term or condition of this Agreement shall 
not constitute a waiver of either party's right to enforce each and every term and 
condition of this Agreement. No breach under this agreement shall be deemed 
waived or excused by either party unless such waiver or consent is in writing signed 
by the party granting such waiver or consent. The waiver by or consent of a party to 
a breach of any provision of this Agreement shall not operate or be construed as a 
waiver of or consent to any other or subsequent breach by such other party.  
 This Agreement may not be assigned (including by operation of law or otherwise) 
by you without WILEY's prior written consent. 
 Any fee required for this permission shall be non-refundable after thirty (30) days 
from receipt by the CCC.  
 These terms and conditions together with CCC�s Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between you 
and WILEY concerning this licensing transaction and (in the absence of fraud) 
supersedes all prior agreements and representations of the parties, oral or written. 
This Agreement may not be amended except in writing signed by both parties. This 
Agreement shall be binding upon and inure to the benefit of the parties' successors, 
legal representatives, and authorized assigns.  
 In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC�s Billing and Payment terms and 
conditions, these terms and conditions shall prevail.  
 WILEY expressly reserves all rights not specifically granted in the combination of 
(i) the license details provided by you and accepted in the course of this licensing 
transaction, (ii) these terms and conditions and (iii) CCC�s Billing and Payment 
185 
 
terms and conditions. 
 This Agreement will be void if the Type of Use, Format, Circulation, or Requestor 
Type was misrepresented during the licensing process. 
 This Agreement shall be governed by and construed in accordance with the laws of 
the State of New York, USA, without regards to such state�s conflict of law rules. 
Any legal action, suit or proceeding arising out of or relating to these Terms and 
Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction of 
such court, waives any objection to venue in such court and consents to service of 
process by registered or certified mail, return receipt requested, at the last known 
address of such party.  
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription 
journals offering Online Open. Although most of the fully Open Access journals publish 
open access articles under the terms of the Creative Commons Attribution (CC BY) 
License only, the subscription journals and a few of the Open Access Journals offer a 
choice of Creative Commons Licenses:: Creative Commons Attribution (CC-BY) 
license Creative Commons Attribution Non-Commercial (CC-BY-NC) 
license and Creative Commons Attribution Non-Commercial-NoDerivs (CC-BY-NC-ND) 
License. The license type is clearly identified on the article. 
Copyright in any research article in a journal published as Open Access under a Creative 
Commons License is retained by the author(s). Authors grant Wiley a license to publish the 
article and identify itself as the original publisher. Authors also grant any third party the 
right to use the article freely as long as its integrity is maintained and its original authors, 
citation details and publisher are identified as follows: [Title of Article/Author/Journal Title 
and Volume/Issue. Copyright (c) [year] [copyright owner as specified in the Journal]. Links 
to the final article on Wiley�s website are encouraged where applicable. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and 
transmit an article, adapt the article and make commercial use of the article. The CC-BY 
license permits commercial and non-commercial re-use of an open access article, as long as 
the author is properly attributed. 
The Creative Commons Attribution License does not affect the moral rights of authors, 
including without limitation the right not to have their work subjected to derogatory 
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treatment. It also does not affect any other rights held by authors or third parties in the 
article, including without limitation the rights of privacy and publicity. Use of the article 
must not assert or imply, whether implicitly or explicitly, any connection with, 
endorsement or sponsorship of such use by the author, publisher or any other party 
associated with the article. 
For any reuse or distribution, users must include the copyright notice and make clear to 
others that the article is made available under a Creative Commons Attribution license, 
linking to the relevant Creative Commons web page. 
To the fullest extent permitted by applicable law, the article is made available as is and 
without representation or warranties of any kind whether express, implied, statutory or 
otherwise and including, without limitation, warranties of title, merchantability, fitness for 
a particular purpose, non-infringement, absence of defects, accuracy, or the presence or 
absence of errors. 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC) License permits use, 
distribution and reproduction in any medium, provided the original work is properly cited 
and is not used for commercial purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) 
permits use, distribution and reproduction in any medium, provided the original work is 
properly cited, is not used for commercial purposes and no modifications or adaptations are 
made. (see below) 
Use by non-commercial users 
For non-commercial and non-promotional purposes, individual users may access, 
download, copy, display and redistribute to colleagues Wiley Open Access articles, as well 
as adapt, translate, text- and data-mine the content subject to the following conditions: 
 The authors' moral rights are not compromised. These rights include the right of 
"paternity" (also known as "attribution" - the right for the author to be identified as 
such) and "integrity" (the right for the author not to have the work altered in such a 
way that the author's reputation or integrity may be impugned).  
 Where content in the article is identified as belonging to a third party, it is the 
obligation of the user to ensure that any reuse complies with the copyright policies 
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of the owner of that content.  
 If article content is copied, downloaded or otherwise reused for non-commercial 
research and education purposes, a link to the appropriate bibliographic citation 
(authors, journal, article title, volume, issue, page numbers, DOI and the link to the 
definitive published version on Wiley Online Library) should be maintained. 
Copyright notices and disclaimers must not be deleted.  
 Any translations, for which a prior translation agreement with Wiley has not been 
agreed, must prominently display the statement: "This is an unofficial translation of 
an article that appeared in a Wiley publication. The publisher has not endorsed this 
translation."  
Use by commercial "for-profit" organisations 
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes 
requires further explicit permission from Wiley and will be subject to a fee. Commercial 
purposes include: 
 Copying or downloading of articles, or linking to such articles for further 
redistribution, sale or licensing;  
 Copying, downloading or posting by a site or service that incorporates advertising 
with such content;  
 The inclusion or incorporation of article content in other works or services (other 
than normal quotations with an appropriate citation) that is then available for sale or 
licensing, for a fee (for example, a compilation produced for marketing purposes, 
inclusion in a sales pack)  
 Use of article content (other than normal quotations with appropriate citation) by 
for-profit organisations for promotional purposes  
 Linking to article content in e-mails redistributed for promotional, marketing or 
educational purposes;  
 Use for the purposes of monetary reward by means of sale, resale, licence, loan, 
transfer or other form of commercial exploitation such as marketing products  
 Print reprints of Wiley Open Access articles can be purchased 
from:corporatesales@wiley.com  
Further details can be found on Wiley Online 
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Libraryhttp://olabout.wiley.com/WileyCDA/Section/id-410895.html 
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
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